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ABSTRACT

A MECHANISTIC STUDY OF THE PROTECTIVE EFFECTS OF SADENOSYL-L-METHIONINE AGAINST HEPATOTOXICITY OF
ACETAMINOPHEN.
by Marcus V. Terneus, Jr.

Hepatic toxicity is known to be associated with excessive doses of the over-thecounter analgesic, acetaminophen (APAP). APAP overdose is the leading cause
of drug-induced liver failure in the United States.

APAP hepatotoxicity is

dependent on the biotransformation of APAP by cytochrome P450 to the toxic
metabolite, N-acetyl-p-benzoquinone imine (NAPQI).

APAP, when taken in

excessive doses, can lead to severe liver damage with the potential to progress
to liver failure. Despite substantial efforts in past studies, the mechanism by
which APAP induces such damaging effects is not completely understood.
Recent discoveries suggest that glutathione (GSH) depletion, protein alkylation
and reactive metabolite formation may all play a part in APAP’s hepatotoxic
effects. The present study hypothesized that S-Adenosyl-L-methionine (SAMe)
diminished APAP hepatic toxicity by maintaining GSH status, reducing oxidative
stress and altering formation of the toxic metabolite. The model selected for this
study was a mouse model which is representative of the human response. This
study was directed at investigating the mechanism by which APAP elicits its
ii

damaging effects on the liver and attenuating that damage with a nutraceutical,
SAMe. Male C57Bl/6 mice were given an intraperitoneal injection (i.p.) of water,
250-500 mg/kg of APAP and/or 500 mg/kg of SAMe. Livers were removed 1-4
hours post-injection and were measured for toxicities using GSH levels, plasma
alanine aminotransferase (ALT) levels, liver:body weight ratios, lipid peroxidation,
histological examinations, protein levels, protein carbonyl levels and oxidized
protein levels. Data showed that APAP had toxic effects at all of the measurable
levels. These data reiterated that APAP was able to elicit damaging effects not
only by GSH depletion, but also by other mechanisms. Pre- and post- treatment
with SAMe attenuated the APAP-induced liver damage successfully in all
measurable parameters compared to the animals dosed with APAP only.

A

further look into the mechanistic properties of SAMe was established after the
initial findings.

These studies included: (1) incorporating a known limiting

reagent, vitamin B6, in SAMe’s pathway to the synthesis of GSH, (2) measuring
and comparing metabolites produced when given APAP only compared to a dose
of SAMe before or after APAP and (4) directly comparing the therapeutic effects
of SAMe to the current antidote to APAP overdose, N-acetylcysteine (NAC). It
was found that not only was SAMe able to reduce and/or eliminate the effects of
APAP overdose, but when given on the same mmol basis, it was able to provide
better protection than NAC. These results strengthen the potential use of SAMe
as an antidote for APAP overdose cases.
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CHAPTER I
Introduction

Acetaminophen (APAP) overdose is a significant medical problem in the
United States as well as other parts of the world, such as Great Britain and
Canada. Intentional and accidental overdose with APAP-containing products is a
primary cause for visits to the emergency room for both children and adults and
accounts for nearly 50% of all acute liver failure in the United States. Toxic
doses of APAP can produce hepatic centrilobular necrosis in human and animal
models.
APAP hepatotoxicity is dependent on biotransformation of APAP by
cytochrome P450 to the toxic metabolite, N-acetyl-p-benzoquinone imine
(NAPQI). Glutathione (GSH) is the body’s natural defense mechanism against
NAPQI and protects the liver from hepatotoxicity by conjugation of this toxic
metabolite. GSH also detoxifies NAPQI and prevents further oxidative stress.
Toxicity elicited by APAP overdose is manifested when GSH stores
become depleted. Despite efforts to investigate APAP-induced liver failure over
the past thirty years, the complete mechanism for this damage is still unknown.
However, an induction of oxidative stress compounded with GSH depletion has
been suggested as part of the cellular mechanism for hepatic damage.
Interventions that increase GSH levels and reduce oxidative stress will limit or
eliminate the effects of APAP toxicity. In the United States, the current antidote
1

for APAP toxicity is oral administration of N-acetylcysteine (NAC). NAC is able to
provide a source of cysteine for increased hepatic synthesis of GSH. However,
NAC does not have a 100% success rate. Time of administration after APAP
overdose and the extent of the amount of APAP taken have a vital effect on the
ability of NAC to reduce liver damage.
S-Adenosyl-L-methionine (SAMe) is a naturally occurring substance that is
present in plasma and most tissues. A healthy adult human produces about 6-8
grams of SAMe per day. SAMe also plays an important part in much of the
body’s reactions, for it is only second to ATP in the variety of reactions where it
serves as a cofactor.

SAMe is also marketed worldwide as a nutritional

supplement. It is available in many vitamin, grocery and health food stores in a
variety of different packaging schemes.
Reasons for SAMe’s ability to reduce or eliminate stress to the liver
induced by APAP lie with its ability to function as a major methyl donor in
transmethylation reactions. Adequate hepatic levels of SAMe are critical since
the liver is responsible for 85% of all transmethylation reactions. SAMe is a
substrate precursor for formation of the tripeptide GSH. It can be converted to SAdenosylhomocysteine and homocysteine which ultimately is converted to
cysteine, the rate limiting factor in the production of GSH. SAMe’s abilities to
attenuate the damaging effects of APAP overdose not only lie with GSH
production.

In our laboratory, we have also seen reduced lipid peroxidation,

plasma ALT and protein carbonyls when animals are dosed with SAMe just prior
or 1 hour after APAP dosing.
2

The goal of the study was to investigate the hypothesis that SAMe can
protect the liver from APAP-induced effects. The study was also designed to
explore the ability of SAMe to attenuate APAP toxicity within 1 - 4 hours after
APAP overdose in a mouse model. Studies further examined the effect of SAMe
on APAP mediated alterations in lipid peroxidation, GSH concentrations, plasma
ALT levels, protein carbonyls and oxidized proteins levels. Investigations also
contained direct comparisons of the protective effects of vitamin B6 + SAMe,
NAC, NAC + SAMe and SAMe. Data collected during this study strengthens the
evidence for the potential use of SAMe as a new antidote for APAP overdose.

3

CHAPTER II
Review of Literature

2.1 Acetaminophen
Acetaminophen (APAP) has been available in the United States since
1960 as an analgesic/antipyretic drug. Since then, APAP has become the most
widely-used analgesic in the United States (Paulose-Ram et al., 2005) as well as
one of the best documented causes of liver damage and/or acute liver failure
(ALF) for over-the-counter medicines (Bae et al., 2001; Langford, 2006; Lee,
2003; Manov et al., 2006). Toxicities include, but are not limited to, induced liver
cell death (Grattagliano et al., 2002; Hinson et al., 1981; James et al., 2003a;
Koo et al., 1987; Goldring, 2004) and nephrotoxicity (Stern et al., 2005). Despite
having comparable analgesic and antipyretic properties as non-steroidal antiinflammatory drugs (NSAIDs), APAP is not classified as an NSAID, because
APAP does not possess any anti-inflammatory properties. Not only has APAP
usage been on the rise, but APAP toxicity has also been steadily increasing
since the 1980s (Björnsson et al., 2006; Russo et al., 2004; Koo et al., 1987;
Goldring, 2004; von Mach et al, 2005).

To date, APAP usage accounts for

approximately 56,000 emergency room visits and 26,000 hospitalizations yearly
in the United States (Nourjah et al., 2006). The majority of overdose cases
involve patients who unintentionally exceeded the recommended APAP amount
(Larson et al., 2006).
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Despite the wide usage of APAP, the direct mechanism of the drug is still
unknown. Although progress has been made in identifying potential mechanistic
properties of APAP, questions still exist about how APAP is metabolized to the
toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI). Some believe that a
cyclooxygenase isozyme might be important in APAP metabolism.

In 1991,

Simmons and coworkers discovered an isozyme of the prostaglandin
synthesizing cyclooxygenase (COX) and named it cyclooxygenase-2 (COX-2)
(Xie et al., 1991; DeWitt, 1999). This enzyme was a remarkable find, mainly
since neither COX-1 nor COX-2 are sensitive to APAP. The COX-2 discovery
has since brought a whole new line of drugs able to more directly fight medical
situations. There is even question of the ability of COX-2 to be a part of a cancer
prevention regimen (Rigas and Kashfi, 2005).

Nearly 11 years after their

discovery of COX-2, Simmons characterized and cloned another COX enzyme in
dog brain which was sensitive to APAP (Chandrasekharan et al., 2002).
However, the field is divided on the possibility of a third COX isozyme. While
some argue that there quite possibly is a COX-3 isozyme that metabolizes APAP
into NAPQI (Botting and Ayoub, 2005), others strongly disagree dismissing
Simmons find as an incompletely spliced mRNA (Meade, 2003).
Even though there are several arguments regarding the mechanism of
APAP hepatotoxicity, there are also some agreements between researchers.
Currently, necrosis is believed to be the initial mode of cell death and apoptosis
has been ruled out (Lawson et al., 1999; Gujral et al., 2002; James et al., 2003).
The reactive metabolite, NAPQI, is formed by a direct two-electron oxidation and

5

elicits its damaging effects in the liver (Dahlin et al., 1984). Recently, it has been
found that cytochromes (CYP) 2E1, 1A2, 3A4, and 2A6 are all involved in the
oxidation of APAP to NAPQI (Patten et al., 1993; Thummel et al., 1993; Chen et
al., 1998; Neve and Ingelman-Sundberg, 2001). There has also been recent
data suggesting that nitrated tyrosine residues, as well as APAP adducts, can
occur in the necrotic cells after receiving toxic doses of APAP (James et al.,
2003; Hinson et al., 2000). These new findings have enabled scientists to move
closer to a fuller understanding of the mechanism by which APAP elicits its
damaging effects.
If taken by a healthy individual under the specified therapeutic guidelines,
APAP can be a very beneficial therapeutic drug.

Under these normal

circumstances, humans can conjugate APAP with sulfate or glucuronide via
sulfotransferase (ST) or uridine diphosphoglucuronosyltransferase (UDPGT),
respectively (Mitchell et al., 1974; Nelson & Bruschi, 2003) (FIGURE 1) and
safely eliminate the conjugated APAP from the body. However, even using the
recommended dose, about 1-2% of the parent APAP compound can be
metabolized (mainly via CYP2E1) into the toxic metabolite, NAPQI. However,
the body has a defense mechanism in the form of glutathione (GSH) that
conjugates NAPQI and allows for its safe removal through the kidneys.
Consequently, APAP can become a very deadly drug if not taken with care.
Intentional and accidental overdose with APAP containing products is a primary
cause for visits to the emergency room for both children and adults (Watson et
al., 2003). In humans, any dose greater than 4 grams per day of APAP can

6

cause acute hepatotoxicity, while a dose of 20 to 25 grams is potentially fatal
(Larson et al., 2006). APAP poisoning is believed to cause at least 42% of acute
liver failure (ALF) cases and 1 in 3 deaths seen in tertiary-care centers across
the Unites States of America (Larson et al., 2006). This problem is also seen in
the United Kingdom and Australia, with 100,000 cases of acute liver failure per
year (Nelson and Bruschi, 2003).

APAP overdose is a significant medical

problem in the United States. In fact, APAP is the most frequent cause of ALF in
this country, which can have up to a 90% mortality rate (Larson et al., 2006; Oz
et al., 2004).
Acetaminophen hepatotoxicity is dependent on biotransformation of APAP
by cytochrome P450 (mostly CYP2E1) to the toxic metabolite, NAPQI (Mitchell et
al., 1973b) (FIGURE 1), however the complete mechanism of this liver injury is
not completely understood (Oz et al., 2004). In the beginning of APAP-induced
hepatotoxicity, toxic doses of APAP produce centrilobular necrosis in zone 3 of
the liver in humans (Davidson and Eastham, 1966; McJunkin et al., 1976) and
animal models (Mitchell et al., 1973a, b; Jollow et al., 1973; Mudge et al., 1978;
Walker et al., 1982). This region around the liver’s central vein is concentrated
with high levels of CYP and low levels of GSH. It is therefore understandable
why this region is the first to show the damaging effects of APAP. The ability of
APAP to generate reactive oxygen species (ROS), sensitive transcription factor
NF-κB, GSH depletion, nitric oxide and lipid peroxides are believed to play a
major role involved with this induced liver injury (Adamson and Harman, 1993;
Blazka et al., 1995; Gordon et al., 1986; Kamiyama et al., 1993; Arnaiz et al.,
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1995; Chen et al., 2005; El-Hassan et al., 2003; Dambach et al., 2006; Gardner
et al., 1998; Ito et al., 2004; Jaeschke et al., 2003; Ozdemirler et al., 1994).
Binding of the toxic APAP metabolite, NAPQI, to target proteins and DNA as well
as mitochondrial GSH depletion also appears to be necessary for toxicity induced
by APAP (Oz et al., 2004; Cohen and Khairallah, 1997; Cover et al., 2005;
Hinson et al., 2004; Bajt et al., 2003). More recently, there has also been data
suggesting that APAP overdose may also cause peroxynitrite formation along
with other forms of oxidative stress (Knight and Jaeschke, 2004; Placke et al.,
1987).
GSH is crucial in the reduction of damage produced by APAP overdose.
This potent endogenous antioxidant is produced from cysteine (also the ratelimiting agent) and protects the liver from hepatotoxicity by conjugation of the
NAPQI’s parent compound (Mitchell et al., 1973a, b). GSH is a tripeptide of γGlutamate-Cysteine-Glycine and is one of the most important compounds in the
defense against chemically reactive compounds and oxidative stress (Sener et
al., 2003; Lomaestro and Malone, 1995; Lucas-Slitt et al., 2005).

GSH also

detoxifies NAPQI (Walker et al., 1982; Potter and Hinson, 1986), adriamycin
(Olson et al., 1980) and naphthalene (Phimister et al., 2004). However, certain
factors such as fasting and ethanol ingestion (induces CYP2E1) when combined
with APAP overdose can deplete hepatic GSH and therefore allow an increase in
hepatotoxicity and mortality (Oz et al., 2004). It is also known that factors such
as the amount of the rate-limiting amino acid, cysteine, can slow down production
of GSH. Studies have shown the effects of GSH deficiency on injury and sepsis,
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and it is therefore understandable that treatment strategies that maintain and/or
increase GSH stores may decrease the incidence of organ failure and death.
Understandably, APAP accounts for many ALF cases, as it is one of the most
commonly used analgesics in the USA and worldwide. Individuals often misuse
APAP both acutely (suicide attempts) and chronically (long-term exposure in
chronic pain patients) (Ellenhorn, 1997). Therefore it is of major scientific and
medical interest to investigate the toxicity associated with APAP because in the
end, patient education, as well as further research investigating antidotes to this
potentially harmful drug, will not only save lives but could also release extra
donor livers to patients on the waiting lists who need livers for other reasons.
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FIGURE 1. Metabolism of APAP. Diagrammatic representation of proposed
metabolic pathway of APAP. The APAP structure is shown at the top, in the
middle of the reaction.

Inside the bracket is a representation of the toxic

metabolite, NAPQI and the binding of GSH to the NAPQI (ST = sulfotransferase,
UDPGT = uridine diphosphoglucuronosyltransferase).
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2.2 N-acetylcysteine
Initial reports of APAP toxicity were described in Dr. Gillette’s laboratory
in the 1970s.

It was found by Dr. Gillette and colleagues that APAP was

metabolically activated by cytochrome P450 (CYP) to some reactive metabolite,
later identified as N-acetyl-p-benzoquinone imine (NAPQI).

NAPQI would

deplete glutathione (GSH) up to 90% and covalently bind to protein.

It was

because of Dr. Gillette’s findings that the antidote (that is still used today), Nacetylcysteine (NAC), was discovered.

Since its initial discovery, there have

been countless studies involving NAC and its protection against APAP-induced
toxicity in rodents (Lauterburg et al., 1983) and humans (Marzullo, 2005). The
studies involving NAC are not limited to APAP.

For example, Raza and

colleagues (2003) investigated the possibility of NAC as an antidote to
azathioprine overdose. The ability of NAC to create GSH through production of
the amino acid (aa) cysteine, makes NAC such an important part of recovery.
Since Gillette’s initial report of APAP toxicity, a number of other events have
been shown to occur during APAP overdose and are likely important in the
initiation and repair of toxicity (James et al., 2003).

However, despite

researchers’ best efforts, scientists still do not fully understand and/or agree upon
the precise mechanisms of hepatocyte death following APAP overdose (Lawson
et al., 1999; Gujral et al., 2002; James et al., 2003).
As mentioned above, NAC is the current antidote to APAP overdose
cases in the United States of America, as well as other countries. NAC is the aa
L-cysteine plus an acetyl group attached to the amino group (FIGURE 2). Oral
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supplementation using NAC can provide a means of boosting intracellular GSH
by acting as a sulfhydryl group donor and raising the rate-limiting compound in
GSH production, cysteine. NAC is rapidly absorbed after oral administration and
reaches a peak plasma level in approximately 2-3 hours, with a half-life of about
6 hours.

In the United States, after an individual has overdosed on APAP,

patients are generally given oral NAC as a 140 mg/kg loading dose followed by
70 mg/kg every 4 hours for 17 more doses. NAC can be difficult to administer
because of its taste and its tendency to cause nausea and vomiting. To maximize
tolerance, it can be diluted down to a 5% solution from its commercially available
10% or 20% solutions (Villar et al., 1998). Even though intravenous forms of
NAC have been available in other countries for some time (Prescott, 1981), the
FDA only recently approved (2004) the administration of NAC through
intravenous route in the United States.

The justification for this route of

administration is to rapidly decrease the damaging effects of APAP quicker.
However, despite the therapeutic effects of NAC in restoring GSH stores,
it is not 100% effective. For NAC to be therapeutically effective, most agree that
it must be given within 8 hours of APAP overdose (Villar et al., 1998). In fact, in
the acute liver failure cases listed above, NAC was administered to all patients
but everyone did not fully recover. While a small percentage of some patients
did fully recover, others had received irreversible damage to the liver and were
placed on the liver transplant list. Some of the patients didn’t even survive after
the NAC treatment.

Questions regarding the potential of NAC as “the best”

antidote for APAP toxicity has previously been raised in the past.
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A study

conducted by Sener and colleagues (2003) compared the protective effects of
three antioxidants: melatonin, vitamin E and NAC. Mice were given one of the
three antioxidants up to 30 minutes prior to APAP injection. These scientists
found that each had therapeutic effects, but it was melatonin that provided better
protection and less damage than vitamin E or NAC. This drives the question as
to whether there is a better antidote for attenuating the damaging effects of
APAP overdose.
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FIGURE 2. Chemical Structure of NAC.
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2.3 S-Adenosyl-L-methionine
S-Adenosyl-L-methionine (SAMe) (FIGURE 3) is a naturally occurring
substance present in plasma and most tissues.

SAMe levels are critical for

normal cellular function (Martinez-Chantar et al., 2002).

SAMe was first

discovered in 1952 and is synthesized from ATP and methionine by the enzyme
S-adenosylmethionine synthetase (Lu, 1998).

SAMe is utilized by three key

metabolic pathways (FIGURE 4): (1) transmethylation, (2) trans-sulfuration and
(3) polyamine synthesis (Friedel et al, 1989; Mato et al., 1999; Lu, 2000).
Transmethylation occurs when a methyl group of SAMe is donated to any large
variety of acceptor substances such as DNA, phospholipids and proteins. Transsulfuration involves the sulfur atom of SAMe. The sulfur atom is converted to
cysteine, a precursor for taurine and glutathione (GSH). Polyamine synthesis
only accounts for about 5% of the SAMe metabolic pathways, but this metabolic
pathway is required for normal cell growth (Lu, 1998) and it can be induced under
conditions of increased polyamine synthesis (Mato et al., 1997).
polyamine

synthesis

can

happen

during

hepatocarcinogenesis (Mudd and Poole, 1975).
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FIGURE 3. Chemical structure of SAMe.
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SAMe is probably second only to ATP in the variety of reactions for which
it serves as a cofactor (Lu et al., 2005). SAMe is a vital metabolic intermediate in
all studied life forms and each cellular organism has enzymes with the ability to
utilize SAMe (Kozbial & Mushegian, 2005). SAMe is also the preferred catabolic
pathway

of

methionine,

where

it

can

then

be

converted

to

S-

adenosylhomocysteine (SAH), which is ultimately converted to cysteine, the ratelimiting reagent in GSH synthesis (Lu et al., 1998) (FIGURE 4). SAMe can be
synthesized in the cytosol of every cell, but the liver plays host to the central role
of SAMe synthesis and degradation. A normal, healthy adult human produces 68 grams of SAMe per day (Lu, 2000). The majority of SAMe is used in the
transmethylation pathway in the liver mainly due to the fact that the liver is
responsible for 85% of all transmethylation reactions (Friedel et al, 1989; Mato et
al., 1997; Lu, 2000). An abundance of SAMe is also used for the catabolic transsulfuration pathway to generate an important antioxidant, GSH (Lu et al., 1998).
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FIGURE 4. SAMe Pathway.
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Glutathione

Despite the body’s abilities to produce SAMe in such large amounts, there
are limiting factors regulating the pathways of SAMe. For instance, SAH is a
potent competitive inhibitor of transmethylation reactions. An increase in SAH
levels and/or a decrease in the SAM:SAH ratio will result in an inhibition of
transmethylation reactions (Finkelstein, 1990; Lu, 2000).

For this particular

reason, removal of excess SAH is essential for the involvement of SAMe in
transmethylation reactions.

In vivo, the reaction represented in Figure 4

proceeds in the forward direction only if the products, adenosine and
homocysteine, are rapidly removed (Mato et al., 1997; Finkelstein, 1990). The
liver plays host to the three pathways that metabolize homocysteine. One of the
pathways includes a transformation of homocysteine to cysteine. This particular
pathway, the trans-sulfuration pathway, is present largely in the liver and the lens
(Lu, 1998). In the trans-sulfuration pathway, serine and homocysteine condense
to form cystathionine in a reaction that requires vitamin B6 as a cofactor (Lu,
2000). Cystathionine is cleaved in a reaction catalyzed by another vitamin B6dependent enzyme into free cysteine (Mato et al., 1997; Lu 1998). Cysteine is a
precursor for taurine and the rate-limiting precursor for GSH synthesis (Lu 1998).
The two other pathways involving the breakdown of homocysteine resynthesize
methionine from homocysteine. One is catalyzed by methionine synthase and
the other is catalyzed by betaine-homocysteine methyltransferase (Mato et al.,
1997; Finkelstein, 1990).
SAMe participates in many major biological functions through its
involvement in the three main metabolic pathways listed above: transmethylation,
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trans-sulfuration and polyamine synthesis. Given the large spectrum of cellular
processes ranging from membrane fluidity (phospholipid methylation) to gene
expression (DNA methylation), it is easy to understand the importance of SAMe
and the issues that can arise when the availability of SAMe is limited by a
disease state or other conditions (Mato et al., 1997; Friedel et al., 1989).
SAMe is commercially available and marketed worldwide as a nutritional
supplement that is readily available in vitamin and health food stores. SAMe
became available in the United States in 1999 as an over-the-counter
nutraceutical (Bottiglieri, 2002). It is currently marketed to provide relief for stiff
joints, provide a healthy liver and create emotional well-being. These marketing
schemes were not created without some evidence.

Regarding past studies,

SAMe has been found to reduce toxic effects of ethanol and carbon tetrachloride
(Song et al., 2003; Garcia-Ruiz et al., 1995; Lieber et al., 1997), APAP
(Valentovic et al., 2004), cytokines, galactosamine, thioacetamide and ischemiareperfusion (Bray et al., 1992; Lieber et al., 1990; Mato et al., 1997; Wu et al.,
1996; Wu and Cederbaum, 2006; Lieber et al., 2002). There was also a study
conducted by Pascale et al. (1993) that investigated the ability of SAMe to
prevent the development of liver cancer in rodents. Exogenous SAMe has also
been shown to decrease the rate of cell growth in a liver cancer cell line (Cai et
al., 1998), treat intrahepatic cholestasis (Frezza et al., 1990) and prevent the
decrease of liver GSH produced by various hepatotoxins (Wu and Cederbaum,
2005).
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The ability of SAMe to participate in such a wide spectrum of reactions in
the body has made it a valuable tool that has the potential to decrease the effects
of different toxicities.

One of the main vital reactions for SAMe is during

situations that cause low GSH levels: ethanol consumption, APAP overdose,
fasting, etc. Our laboratory (Valentovic et al., 2004) and others (Stramentinoli et
al., 1979; Bray et al., 1992; Carrasco et al., 2000; Song et al., 2004) have further
investigated the potential of SAMe attenuating chemical-induced forms of liver
toxicity.
Due to the major part APAP plays in so many different people’s lives every
day and the vast increase in APAP toxicity reported around the world, we had
decided to study the potential of SAMe as an antidote for APAP overdose cases.
In vivo experiments were designed using male C57Bl/6 mice. Mice were chosen
as an in vivo model based on their ability to metabolize APAP similarly to
humans. Significant differences can exist with respect to various species to the
hepatotoxic effects of APAP. For instance, rats, rabbits and guinea pigs are
somewhat resistant to APAP-induced liver injury, most likely due to their ability to
excrete higher amounts of APAP metabolites through the kidney (Bessems and
Vermeulen, 2001). The C57Bl/6 mice were dosed with APAP based on previous
mouse studies (Bray et al., 1992; Carrasco et al., 2000; Stramentinoli et al.,
1979; Song et al., 2004). SAMe doses were given as an intraperitoneal (i.p.)
injection just prior or post-APAP treatment and were comparable to doses used
in previous studies (Carrasco et al., 2000; Stramentinoli et al., 1979; Song et al.,
2004).
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One of the protective mechanisms of SAMe is believed to include the
production of GSH. After GSH reduces an active metabolite, such as NAPQI,
GSH then becomes oxidized. Oxidized GSH is inactive and cannot protect the
liver from damage.

GSH can be converted back to its reduced form by

glutathione reductase. The effects of SAMe on glutathione reductase are not
known. If SAMe increases the activity of glutathione reductase, this too could be
another protective mechanism of SAMe. GSH in the presence of glutathione
peroxidase can donate one electron to NAPQI and convert it back to APAP.
Glutathione peroxidase activity is dependent on high GSH levels and its activity
is diminished in conditions of GSH depletion. SAMe may provide sufficient GSH
to maintain intact glutathione peroxidase activity, which would lessen the levels
of NAPQI.

To further understand the mechanistic properties of SAMe, our

studies give a better description of how and where SAMe initiates GSH synthesis
within the cell.
SAMe has been shown to reduce APAP-induced heptatotoxicity by our
laboratory (Valentovic et al., 2004) as well as others (Stramentinoli et al., 1979;
Bray et al., 1992; Carrasco et al., 2000; Song et al., 2004). SAMe administration
just prior to, as well as after, APAP treatment greatly diminished the extent of
centrilobular necrosis in C57Bl/6 male mice when compared to animals given
only APAP (Valentovic et al., 2004). SAMe has also shown beneficial effects in
reducing and reversing hepatic damage induced by alcohol in humans (Lieber,
2002)

and

in

intrahepatic

cholestasis
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(Frezza

et

al.,

1990).

CHAPTER III
Materials
Chemicals/Equipment Including Sources (Company & Catalog Number)
Acetic acid (Fisher, UN-2789)
N-acetylcysteine (NAC) (Sigma, A-8199)
Acrylamide (Fisher, BP170)
Ammonium Persulfate (APS) (Fisher, BP179)
Anti-Nitrotyrosine rabbit immunoaffinity purified IgG (Upstate, 06-284)
Bis-acrylamide (Bio-Rad, 161-0201)
Bromophenol blue (Pharmacia Biotech, 17-1329-01)
N-butanol (Sigma, BT-105)
Coomassie brilliant blue (Calbiochem, 234735)
Disodium EDTA (Fisher, S-311)
5,5’-Dithiobis(2-nitrobenzoic acid) (Aldrich, D21820-0)
ECL Western Blot Kit (Amersham Biosciences, RPN2106)
Ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA) (Sigma, E5134)
Glutathione disulfide (GSSG) (Sigma, G-6654)
Glutathione reductase (Sigma, G-3664)
Glycerol (Fisher, BP229)
Glycine (Sigma, G7126)
Goat anti-rabbit IgG – HRP (Santa Cruz Biotechnology, SC-2004)
Infinity ALT kit (Thermo, TR71021)
2-Mercaptoethanol (2-ME) (Fisher, BP-176-100)
Methanol (Fisher, AY12-20)
NADPH (Sigma, N-7505)
Nitrotyrosine immunoblotting control (Upstate, 12-354)
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Opitran 0.45µm supported nitrocellulose membrane (Whatman, BA-585)
OxyBlot Protein Oxidation Detection Kit (Chemicon International, S7150)
Polyclonal antibody to (e)-4-hydroxynonenal (Alexis Biochemicals, ALX-210-767)
Polyclonal antibody goat anti-rabbit (Santa Cruz Biotechnology)
Ponceau (Sigma, P3504)
Potassium chloride (Fisher, P-217)
Potassium phosphate monobasic (Fisher, P-285)
Reduced glutathione (GSH) (Sigma, G-6529)
S-Adenosyl-L-methionine p-toluenesulfonate (Sigma, A2408)
Sodium chloride (Fisher, S671-3)
Sodium dodecyl sulfate (SDS) (Fisher, L-4390)
Sodium phosphate dibasic anhydrous (Mallinckrodt, 7917)
5-Sulfosalicyclic acid (SSA) (EMD, SX 1220-1)
TEMED (Sigma, T9281)
2-Thiobarbituric acid (Sigma, T-5500)
Trichloroacetic acid (Fisher, A322-500)
Triethanolamine (Sigma, T1377)
Trizma Base (Sigma, T6066)
TWEEN-20 (Sigma, P-1379)
2-Vinylpyridine (Aldrich, 13229-2)
0.45µm syringe filter (Durapore; Millex-HV)
Dubnoff metabolic shaker (Precision Scientific; Chicago, IL)
Sorval MC12V centrifuge
Guilford Stasar II Spectrophotometer
Beckman 126 model HPLC
Bio-Rad transblot apparatus
BRL vertical gel V-16 electrophoresis system

24

Methods
Selection of Animal Species and In Vivo Model
The male C57Bl/6 mouse animal model was selected for this project
because it has been shown that these mice have susceptibility to hepatic
toxicants similar to that of humans (Bessems and Vermeulen, 2001). Previous
studies have also shown that acetaminophen (APAP) is hepatotoxic in this
animal model (Carrasco et al., 2000; Bray et al., 1992; Stramentinoli et al., 1979).
Male mice were chosen to minimize hormonal variations in the model.
Male C57Bl/6 mice (16-20 g) were obtained from Hilltop Lab Animals, Inc.
(Scottsdale, PA, USA). Animals were maintained under a controlled ambient
temperature (21-23°C), humidity (40-55%) and light cycle (lights on 0600-1800
h). Animals were provided free access to tap water and Rodent Chow. All mice
were given a minimum 7-day acclimation period prior to initiation of any
experiments. This model was the only animal model used throughout the study.
The animals were given an intraperitoneal (i.p.) injection of water, APAP,
S-Adenosyl-L-methionine (SAMe), N-acetylcysteine (NAC), vitamin B6, diethyl
maleate (DEM) and/or corn oil. These treatments were chosen on the basis that
this model provides an overall look at how the body reacts to an overdose of a
toxicant such as APAP. It also allows for a realistic view of how we could expect
the liver to react/look after a severe overdose of APAP. This model allowed cells
to maintain communication and metabolism.

Furthermore, the in vivo model

avoided confounding factors that may be seen in cell culture models where
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results cannot be directly compared to what would be expected in real-life
situations.
Treatment of Animals with SAMe just prior to APAP
Each experiment consisted of 20 fasted animals randomly separated into
4 different groups with 5 animals per group. Experiments included animals that
were fed and those that were fasted overnight (1700 – 0900 h).

These

experiments are labeled in the results section. The first group, designated as the
vehicle (VEH), was injected i.p. with water (15 ml/kg). The second group was
injected (i.p.) with 500-1000 mg/kg of SAMe (5 ml/kg) only. This allowed a direct
comparison to the VEH animal to confirm that the SAMe treatment did not have
any toxic effects. The third group was given an i.p. dose between 250-500 mg/kg
of APAP (15 ml/kg). The fourth and final group was given 500-1000 mg/kg of
SAMe just prior to 250-500 mg/kg of APAP. After treatment, the mice were
anesthetized with CO2 by inhalation and blood was collected by cardiac
puncture. The mice were laparotomized, the abdominal aorta severed and the
liver was excised 1-4 hours post-APAP and placed in ice-cold Krebs-Ringer
buffer. Blood collected from the animals was spun at 10,000 xg for 10 minutes at
room temperature to separate the plasma. ALT assays (Infinity Kit #TR71021)
were performed on the plasma as a parameter of hepatic function.
Treatment of Animals with NAC just prior to APAP
Animals were fasted overnight (1700 – 0900 h), prepared and divided into
groups as described above. However, in these experiments animals were given
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the same 1.25 mmol/kg dose of NAC, i.p., as SAMe.

The first group was

designated as the VEH, the second received (i.p.) with 204 mg/kg of NAC (5
ml/kg at pH 7), the third group received 250-500 mg/kg of APAP and the final
group was given 204 mg/kg of NAC just prior to 250-500 mg/kg of APAP. After
treatments, livers were excised 1-4 hours post-APAP injection.
Treatment of Animals with DEM after SAMe or NAC
Animals were fasted overnight (1700 – 0900 h) and randomly divided into
three groups with five animals per group. The first group (VEH) received an i.p.
injection of 15 ml/kg corn oil. The second group received 1000 mg/kg DEM. The
third group received (i.p.) 1000 mg/kg DEM just after 500 mg/kg SAMe or 204
mg/kg NAC. Livers were removed 2 or 4 hours post-DEM treatments.

Treatment of Animals with SAMe + NAC just prior to APAP
Animals were fasted overnight (1700 – 0900 h) and randomly divided into
four groups, as described previously. The first group contained animals dosed
with water and were designated “VEH”. The second group received a total 0.625
mmol/kg SAMe and NAC, i.p., injected as 250 mg/kg SAMe + 102 mg/kg NAC.
The third group received 300 mg/kg APAP and the fourth group received 250
mg/kg SAMe + 102 mg/kg NAC just prior to 300 mg/kg APAP. After i.p. injection,
the livers were excised 1 or 4 hours post-APAP injection.
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Treatment of Animals with Vitamin B6 + SAMe just prior to APAP
Animals were fasted overnight (1700 – 0900 h) and prepared as described
above. The first group was given water and labeled as the VEH, the second
group received 3.84 mg/kg vitamin B6 + 500 mg/kg SAMe, the third group was
treated with 300 or 400 mg/kg APAP and the final group was injected i.p. with
3.84 mg/kg vitamin B6 + 500 mg/kg SAMe just prior to 300 or 400 mg/kg APAP.
After injections, livers were excised 1 or 4 hours post-APAP administration.
Experiments Involving SAMe or NAC Dosing Post-APAP Overdose
Animals were fasted overnight (1700 – 0900 h) and randomly divided into
four groups with five animals per group. The first group received an i.p. injection
of water (VEH). The second group received an i.p. injection of either 500 mg/kg
SAMe or 204 mg/kg NAC. The third set of animals received 250 mg/kg of APAP.
The final group received 250 mg/kg APAP 1 hour prior to 500 mg/kg SAMe or
204 mg/kg NAC. Blood was collected and livers were excised 4 hours postAPAP.

Isolation of Livers
Food was removed the evening prior to all experiments involving fasting
(1700-0900 h). The initial studies included fed animals and are explained in
further detail in the results section.

During the initial studies, animals were

allowed free access to both food and water. All other studies were conducted on
animals that had been fasting but were still allowed free access to water. The
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afternoon of the experiments, animals were anesthetized within a carbon dioxide
(CO2) chamber.

Blood was removed via cardiac puncture using 22-gauge

needle on a 1 cc syringe and stored in microcentrifuge tubes.

After blood

removal, the cervical vertebrae were dislocated to kill the animals. The liver
(FIGURE 5) was then removed, trimmed of unwanted tissues (skin, intestines,
diaphragm and/or spleen) and immediately placed in 3 ml of ice-cold KrebsRinger buffer (see Appendix for preparation of Krebs-Ringer buffer preparation)
or Buffer A (see Appendix for preparation of Buffer A) for mitochondrial isolation
experiments. The total liver tissue was blotted dry, weighed and separated into
specified amounts for each assay. Assay measurements included GSH, protein
and lipid peroxidation levels. Each assay had specific ways to store the tissues
and is further discussed and described below. Blood collected from the animals
was centrifuged at 10,000 xg for 10 minutes at room temperature to separate the
plasma.

Plasma was collected and stored at 4°C in a second set of

microcentrifuge tubes.
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FIGURE 5. Diagram of Mouse Anatomy.
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Mitochondrial Isolation
A series of studies examined the subcellular effects of APAP on hepatic
mitochondria and whether SAMe localized in a specific organelle.

Other

experiments required mitochondrial isolation to assess the damage of APAP as
well as the protection provided by either SAMe or NAC in attenuating APAPinduced damage. After collection of blood, liver was excised, blotted, weighed
and minced using sharp-pointed scissors. Blood collected from the animals was
spun at 10,000 xg for 10 minutes at room temperature to separate the plasma.
ALT assays (Infinity Kit #TR71021) were performed on the plasma as a
parameter of hepatic function. The liver samples were hand homogenized on ice
in 1.5 ml of Buffer A using a dounce tissue grinder. Homogenized tissues were
collected and the grinders were rinsed with 1.5 ml of Buffer A and the rinse buffer
added to the sample. The 3 ml samples were then centrifuged at 600 xg for 10
minutes at 4°C. Supernatant was then removed and spun at 15,000 xg for 5
minutes at 4°C. After the 15,000 xg spin, the supernatant (cytosolic content) was
removed and stored in microcentrifuge tubes for GSH determination, protein
concentrations and LDH assays (to confirm mitochondria were isolated). The
pellet created after the 15,000 xg spin is mitochondrial based components. The
pellet was rinsed with 250 µl of Buffer B (see Appendix for preparation of Buffer
B). The pellet was then resuspended in 1 ml of Buffer B per gram of tissue
weight.

The resuspension was then divided into tubes to perform GSH

determination, protein concentration and LDH levels. See Appendix for further
details regarding mitochondrial isolation.
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LDH Assay
Upon completion of centrifugation for mitochondrial isolation, cytosolic and
mitochondrial lactate dehydrogenase (LDH) levels were determined using a
spectrophotometric kinetic assay designed by Sigma (Sigma, Kit #228). The
principle for the assay uses LDH to catalyze the oxidation of lactate to pyruvate
with the simultaneous reduction of NAD (FIGURE 6). The formation of reduced
nicotinamide adenine dinucleotide (NADH) results in an increase of absorbance
at 340 nm. The rate of absorbance is directly proportional to LDH activity. LDH
release was expressed as percent of total LDH.

LDH
Lactate + NAD

Pyruvate + NADH

FIGURE 6. Reaction involved in LDH assay.
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Glutathione Determination
After liver was blotted and weighed, 200 ± 15 mg were collected and
homogenized in 5% sulfosalicylic acid (SSA) in a 1 ml total volume. Total GSH
was determined by an enzymatic reaction with glutathione reductase using 5,5’dithiobis(2-nitrobenzoic acid) and NADPH (Anderson, 1985).

Glutathione

disulfides (GSSG) were measured on samples derivatized with 2-vinylpyridine
(Griffith, 1980) prior to enzymatic measurement of GSH (nonspecific). Values
were expressed as nmol/g tissue or µmol/g tissue. See Appendix for detailed
methods.
Lipid Peroxidation
Thiobarbituric acid reactive substances (TBARS) were measured in the
homogenized liver samples as a measure of lipid peroxidation.

Livers were

collected from each group as described previously. Liver samples (300 ± 15 mg)
were homogenized in 1.5 ml of Krebs-Ringer buffer. The homogenizer probe
was rinsed with an additional 1.5 ml of Krebs-Ringer buffer and the sample
volume was adjusted to 3 ml. A 1.5 ml aliquot was divided evenly between two
microcentrifuge tubes and used for protein concentration determination.

The

other 1.5 ml homogenate volume was added to an equivalent volume of 15%
trichloroacetic acid (TCA) dissolved in 0.25 N HCl. Protein was precipitated for
15 min on ice, and the supernatant was collected following centrifugation (2000
xg at 4°C, 10 minutes). The supernatant was heated for 15 minutes at 90°C with
an equal volume of 0.67% thiobarbituric acid (Udea and Shah, 1996). Following
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a 10 minute cooling period, the absorbance was measured at 535 nm. The
amount of TBARS was calculated based on a standard curve using
malondialdehyde (MDA) and expressed as µmol MDA/mg protein.

Protein Determination
Livers were collected and prepared as described in the lipid peroxidation
section. The 1.5 ml aliquot collected before lipid peroxidation determination was
stored at -80°C until analysis.

Protein concentrations were analyzed as

described by Bradford (1976).

4-Hydroxy-2-nonenal-Adducted Protein
Animals were treated and livers collected as described above.

Liver

tissues were weighed and then homogenized in Krebs-Ringer buffer in a 1
ml/100 mg of tissue total volume.

Western blots were used to look for the

presence of 4-hydroxy-2-nonenal (4HNE)-adducted proteins. See Appendix for
detailed methods.
Protein Carbonyl Determination
Animals were treated and livers collected as described previously. Livers
were weighed and then homogenized in Krebs-Ringer buffer in a total volume of
1 ml of buffer per 100 mg tissue. An OxyBlot kit (Chemicon International, S7150)
was used to calculate the total concentration of protein carbonyls present. An
antibody specific to regions on protein carbonyls derivatized with 2,434

Dinitrophenylhydrazine (DNPH) included in the OxyBlot kit was used (FIGURE
7).
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FIGURE 7. Reaction involving derivatization of protein with DNP.
Region highlighted represents the area recognized by the primary antibody
included with the OxyBlot kit.
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Oxidative Stress
The role of oxidative stress in APAP toxicity was evaluated using three
approaches: GSH status, 4HNE-adducted protein determinations and production
of protein carbonyls through measurement using the OxyBlot kit. These methods
are described above.

Proteomics
Proteomic data represented in the results section were generated in
collaboration with Serrine Lau, PhD at the University of Arizona. Protein samples
were prepared as explained above in the protein determination section and
protein concentrations were calculated using the Bradford Assay. Samples were
analyzed by Dr. Lau’s laboratory to complete the identification of proteins in
question.

Dr. Lau is Director of the proteomics center at the University of

Arizona.
The following methods were written in collaboration with Dr. Lau’s
laboratory. It illustrates the steps performed after receiving samples from our
laboratory:

Initial sample preparation:

Samples were received from Marshall University

frozen on dry ice and promptly placed in a -80oC freezer. The samples were
thawed on ice and approximately 100 µL of whole tissue homogenate was spun
at 14,000 rpm for 5 minutes at 4oC.

Then the supernatant (soluble protein

fraction) was transferred to a clean tube on ice.
37

Oxyblot: The exact protocol from Chemicon International was followed using 18
µg of protein/lane (OxyBlot Protein Oxidation Detection Kit S7150).

Gel Electrophoresis: Approximately 40 µg of protein was added to each lane of a
12% gel (Invitrogen) and separated for 1.5 hours at a constant 150 volts. The gel
was then stained overnight with Coomasie blue.

LC/MS-MS: Analyses of in-gel trypsin digested H3.3 protein bands were carried
out using a quadruple ion trap ThermoFinnigan LCQ DECA XP PLUS (San Jose,
CA) equipped with a Michrom Paradigm MS4 HPLC, and a nanospray source
based on the design of the University of Washington. Peptides were eluted from
a 15 cm pulled tip capillary column (100 µm I.D. x 360 µm O.D; 3-5 µm tip
opening) packed with 8-9 cm Vydac C18 (Hesperia, CA) material (5 μ, 300Å pore
size), using a gradient of 0-65% solvent B (98% methanol/ 2% water/ 0.5%
formic acid/ 0.01% triflouroacetic acid) over a 60 minute period at a flow rate of
200-300 nl/min. The LCQ ESI positive mode spray voltage was set at 1.6 kV, and
the capillary temperature at 200°C. Dependent data scanning was performed by
the Xcalibur v 1.3 software, with a default charge of 2, an isolation width of 1.5
amu, an activation amplitude of 35%, activation time of 30 msec, and a minimal
signal of 10,000 ion counts. Global dependent data settings were as follows:
reject mass width of 1.5 amu, dynamic exclusion enabled, exclusion mass width
of 1.5 amu, repeat count of 1, repeat duration of 1 minute, and exclusion duration
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of 5 minutes. Scan event series included one full scan with mass range 350 –
2000 Da, followed by 3 dependent MS/MS scan of the most intense ion.

Data Analysis:

The criteria that were used for preliminary positive peptide

identification are the same as previously described. All matched peptides were
confirmed by visual examination of the spectra. All spectra were searched
against the latest version of the non-redundant protein database downloaded
from the National Center for Biotechnology Information (NCBI).

Computer Program Descriptions for Data Analysis:
Turbo SEQUEST: Tandem MS spectra of peptides were analyzed with Turbo
SEQUEST™, a program that allows the correlation of experimental tandem MS
data with theoretical spectra generated from known protein sequences.

X!Tandem: Is an open source software program that matches tandem mass
spectra with peptide sequences. It identifies and scores possible peptides and
their corresponding proteins from the MS/MS data, and is capable of searching
the input data for specified amino acid additions.

SALSA: (scoring algorithm for spectral analysis) Is a program that is capable of
identifying and scoring spectra that contain a specified neutral loss of a user
specified modification, such as a phosphate or small molecule. Spectra showing
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promising scores are then compiled into DTA files and processed using
X!Tandem.

PMOD: Algorithm screens data files for MS-MS spectra corresponding to peptide
sequences in a search list. Modification of the primary peptide sequence will
result in a shift in the peptide mass. This shift in the peptide mass may be
experimentally observed as a difference between the measured mass of the
modified peptide precursor ion (adjusted for charge state) and the predicted
mass of the unmodified peptide. If a modification is located at a particular amino
acid residue in the sequence, the mass shift also will be observed in the m/z
values of some of the fragment ions.

SpecPlot: Is a novel program that generates theoretical b and y ions from a user
specified peptide containing an adduct. It then compares the theoretical ions to a
spectrum from raw data specified by the user and shows which ions correlate
between the two. Essentially, it increases throughput of manual validation of
adducted peptides, which is a requirement for acceptance.

High Performance Liquid Chromatography (HPLC)
HPLC methods used were similar to Moldéus (1978) and Vertzoni and
colleagues (2003). Metabolites were quantified and normalized to a standard
curve (concentration of 0-125 µg/ml). Standard curves were established using
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APAP, acetaminophen glucuronide and acetaminophen sulfate.

Plasma and

liver samples were prepared as described above. As described in the methods
published by Vertzoni (2003), 50 µl and 30 µl of an internal standard are
combined in a microcentrifuge tube. A volume of 30 µl of HClO4 and 190 µl of
water are also added to the mixture (total volume of 300 µl). The sample is then
vortexed for 1 minute and spun at 11,000 rpm for 10 minutes at room
temperature. The supernatant can then be stored at -20°C or filtered with a 0.45
µm syringe filter. After filtration, 20 µl is injected and ran on the Beckman 126
model HPLC using a mobile phase similar to that published in Moldéus (1978).

Statistical Analyses
All statistical calculations were performed using SigmaStat software
package (version 2.03). Values were reported as a mean ± SEM. Differences
between groups were analyzed using a repeated-measures analysis of variance
(RM-ANOVA) followed by a Newman-Keuls or Tukey test at a 95% confidence
interval (Sokal and Rohlf, 1969). All groups consisted of 4-10 animals.
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CHAPTER IV
Results
4.1 General Toxicity
Since acetaminophen (APAP) biotransformation is similar between
humans and mice, the APAP dosages were selected to closely mimic a human
overdose. The doses of APAP selected were 250-500 mg/kg. In this study,
APAP was directly toxic to the liver as noted by glutathione (GSH) depletion,
elevated plasma ALT levels, increased liver: body weight ratio and abnormal
morphology viewed using light microscopy. APAP induced both concentrationand time-dependent hepatotoxicity as indicated by the following studies. The
toxic effects were observed with concentrations as low as 250 mg/kg APAP.
These studies reiterate the harmful effects of APAP to the body, especially the
liver, and how it alters tissue viability as measured by GSH levels, plasma ALT
levels, liver:body weight ratio, protein levels, lipid peroxidation and histology
studies.
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4.2 Treatments Just Prior to APAP
4.2.1 Time- and Dose-Dependent APAP Toxicity in Fed Mice
Effect of 1000 mg/kg or 500 mg/kg SAMe just prior to 500 mg/kg APAP dose
Initial studies examined the protective effect of SAMe on APAP hepatic
toxicity in fed mice. The concentration of SAMe was chosen based on results
published in past studies (Stramentinoli et al., 1979; Bray et al., 1992), as well as
what we had seen in our laboratory (Valentovic et al., 2004).

It has been

postulated (Lu, 1998) that one of the protective mechanisms of SAMe is to
induce production of GSH (FIGURE 4). GSH is then able to bind to either Nacetyl-p-benzoquinone imine (NAPQI) or the parent compound, APAP, and the
conjugated pair is then eliminated from the body (FIGURE 8). Therefore, we
examined the effects on GSH production when SAMe was administered just prior
to APAP.
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FIGURE 8. GSH conjugation of APAP and NAPQI.
The left side of the figure represents GSH conjugation of APAP. The right side
shows the ability of GSH to attach itself and inactivate NAPQI. The highlighted
region represents the area upon which GSH conjugates the compound.
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During our initial studies, we used an APAP dose of 500 mg/kg. The male
C57Bl/6 mice (16 – 22 g) were divided into four treatment groups (TABLE 1):
control treated (VEH), APAP treated (APAP), SAMe treated (SAMe) and SAMe
pretreatment just prior to APAP (SAMe + APAP).

SAMe was administered

intraperitoneal (i.p.) at a dose of 500 or 1000 mg/kg (5 ml/kg in water) and given
just prior to APAP. APAP was administered i.p. at a dose of 500 mg/kg (15
ml/kg). The VEH group was injected with water (15 ml/kg). These first studies
included animals that were not fasted. The mice had free access to both food
and water.
APAP hepatotoxicity was evaluated 2 and 4 hours post-APAP treatment.
The following results have been published (Valentovic et al., 2004).

APAP

hepatic toxicity was confirmed by increased liver weight, elevated plasma ALT
values and histological alterations. APAP increased liver weight within 4 hours
when compared to the VEH group (TABLE 2). Liver weight was not altered 2
hours after APAP injection in these fed animals. APAP increased (p < 0.05)
plasma ALT levels (TABLE 3) above VEH values 2 and 4 hours post-APAP
injection. APAP-induced hepatotoxicity was reduced by the SAMe pretreatment.
Both SAMe pretreatment doses prevented the increase in liver weight attributed
to APAP treatment at all time periods. Both doses of SAMe injected prior to
APAP prevented the APAP induced rise in plasma ALT levels. These findings
support the hypothesis that SAMe attenuates APAP toxicity.
Examination by light microscopy showed normal morphology for the VEH
treated group at 2 hours (FIGURE 9a) and 4 hours (FIGURE 10a). Within 2
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hours of APAP treatment, moderate focal centrilobular changes were observed
(FIGURE 9c). SAMe (1000 mg/kg) pretreatment showed slight changes in the
centrilobular region at 2 hours (FIGURE 9b) and 4 hours (FIGURE 10b). The
SAMe + APAP group showed less damage within the centrilobular region at both
time points (FIGURES 9d and 10d). High power magnification of 4 hour tissue
samples showed extensive centrilobular necrosis in the APAP group and almost
complete protection in the SAMe + APAP group (FIGURES 10e and 10f).
Lipid peroxidation was increased within 2 hours after APAP injection when
compared to all other groups (FIGURE 11). Lipid peroxidation continued to be
increased at 4 hours after treatment in the APAP group. SAMe (1000 mg/kg)
treatment just prior to APAP prevented an increase in lipid peroxidation in the
SAMe + APAP group when compared to the SAMe or VEH groups (FIGURE 11).
Lipid peroxidation levels were comparable between VEH and SAMe groups.
SAMe pretreatment just prior to APAP prevented a rise in lipid peroxidation 2 and
4 hours after APAP injection.
Pretreatment with a lower dose of SAMe (500 mg/kg) just prior to APAP
also prevented a rise in lipid peroxidation (FIGURE 12). These results indicate
that pretreatment with 500 mg/kg rather than 1000 mg/kg SAMe prevented the
rise in lipid peroxidation induced by APAP. The prevention of APAP mediated
rise in lipid peroxidation by the administration of 500 mg/kg SAMe (not 1000
mg/kg SAMe) just prior to APAP may have allowed the liver to utilize the SAMe
more efficiently instead of overloading the liver with too much SAMe. It also
reiterated the conclusion first published by Lu (1998) that if the ratio of
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SAH:SAMe favors SAH, the reaction to produce GSH is reversed and no GSH is
made.
GSH levels were markedly diminished within 2 hours after APAP injection
when compared to the VEH group (FIGURE 13). GSH levels continued to be
severely diminished in the APAP group 4 hours after treatment when compared
to the VEH group (FIGURES 13 and 14). SAMe administration (1000 mg/kg) did
not alter baseline GSH levels (FIGURE 13). However, the 500 mg/kg dose of
SAMe resulted in a small increase (p < 0.05) in baseline GSH levels when
compared to the vehicle (FIGURE 14). The increase in baseline GSH levels may
be attributed to rapid tissue handling and immediate treatment with sulfosalicylic
acid (SSA) to prevent degradation of GSH.
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Group
VEH
APAP
SAMe
SAMe + APAP

APAP
No
Yes
No
Yes

SAMe
No
No
Yes
Yes

TABLE 1. SAMe and APAP treatment regimens.

Group

SAMe dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g)

Liver weight
(g/10g body wt.)
a

VEH
APAP
SAMe
SAMe + APAP

0
0
1000
1000

2
2
2
2

20.4 ± 0.4
18.0 ± 0.6
19.6 ± 0.7
18.0 ± 0.6

0.60 ± 0.01
0.59 ± 0.04a
a
0.58 ± 0.02
0.59 ± 0.04a

VEH
APAP
SAMe
SAMe + APAP

0
0
1000
1000

4
4
4
4

25.2 ± 0.5
25.0 ± 0.4
25.6 ± 0.8
25.4 ± 0.7

0.48 ± 0.01a
0.55 ± 0.01b
a
0.45 ± 0.02
0.46 ± 0.02a

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

19.6 ± 0.50
19.2 ± 0.33
19.5 ± 0.40
19.0 ± 0.45

0.42 ± 0.02
b
0.56 ± 0.03
a
0.42 ± 0.02
a
0.49 ± 0.02

a

TABLE 2. Body and liver weight following APAP administration.
APAP was administered as 500 mg/kg (15 ml/kg), i.p. SAMe was administered
as 500 or 1000 mg/kg (5 ml/kg), i.p. Values are reported at mean ± SEM with n =
4-10 animals/group.

Groups with different superscripts denote statistical

difference (p < 0.05) within each treatment experiment.
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Group

SAMe dose
(mg/kg)

Time
post-APAP
treatment (h)

ALT (U/l)

VEH
APAP
SAMe
SAMe + APAP

0
0
1000
1000

2
2
2
2

34 ± 12
185 ± 50a
63 ± 19
73 ± 9

VEH
APAP
SAMe
SAMe + APAP

0
0
1000
1000

4
4
4
4

25 ± 1
376 ± 160a
76 ± 34
54 ± 24

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

23 ± 2
315 ± 62a
55 ± 14
104 ± 63

TABLE 3. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 500 mg/kg;
S-Adenosyl-L-methionine (SAMe)

i.p.

injected

1000

mg/kg;

SAMe and

acetaminophen (SAMe + APAP) at doses listed for individual agents. Unlike
letters (a) indicate groups are different (p < 0.05) from each other using a one
way ANOVA and Tukey’s post hoc test. Values represent mean ± S.E.M. with n
= 5 per group.
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Comment [V1]: Need to change the
alignment for the ALT values so that all
the ± are in the same column, it looks
better. Check any publication and you will
see the ± are all aligned

Centrilobular
Regions

FIGURE 9. Histological examination 2 hours after APAP injection.
Hepatic tissues were prepared and stained with H&E. Representative slides of
(a) vehicle (VEH); (b) SAMe (1000 mg/kg) pretreated; (c) 2 hours postacetaminophen (APAP) injection and (d) mice treated with SAMe and APAP.
Normal morphology was noted in the VEH and SAMe animals. Moderate damage
was noted in the APAP group and is labeled with arrows. Magnification is 200×.
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Centrilobular
Regions

FIGURE 10. Histological examination 4 hours after APAP injection.
Hepatic tissues were collected 4 hours after APAP injection and stained with
H&E. Representative slides are of (a) vehicle (VEH); (b) SAMe only; (c) 4 hours
post-acetaminophen (APAP) injection; (d) mice treated with SAMe and APAP; (e)
4 hours post APAP injection; (f) mice treated with SAMe and APAP. Normal
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morphology was noted in the VEH and SAMe animals. Centrilobular necrosis
was apparent in the APAP group around the central vein. The SAMe + APAP
group had moderate changes in the centrilobular region. Magnification is 200x for
(a)–(d) and 400x for (e)–(f).
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FIGURE 11. Lipid Peroxidation following APAP injection in C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 500 mg/kg
treated (APAP), SAMe 1000 mg/kg treated (SAMe) and SAMe and APAP treated
(SAMe + APAP). Values represent mean S.E.M., n = 4–6 mice per group. Lipid
peroxidation was measured 2 and 4 hours after injection (i.p.) of 500 mg/kg
APAP. Lipid peroxidation was measured as µmol malondialdehyde (MDA)/mg
protein. Groups with unlike superscripts are statistically different.
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FIGURE 12. Lipid Peroxidation 4 hours post-APAP injection in C57Bl/6
mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 500 mg/kg
treated (APAP), SAMe 500 mg/kg treated (SAMe) and SAMe and APAP treated
(SAMe + APAP). SAMe was administered just prior to APAP injection. Values
represent mean S.E.M., n = 4–6 mice per group. Lipid peroxidation was
measured 2 and 4 hours after injection (i.p.) of 500 mg/kg APAP. Lipid
peroxidation was measured as µmol malondialdehyde (MDA)/mg protein. Groups
with unlike superscripts are statistically different.

SAMe + APAP group is

statistically different (p < 0.05) from the APAP group as designated by “c”.
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FIGURE 13. Total hepatic glutathione levels following APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 500 mg/kg
treated (APAP), SAMe 1000 mg/kg treated (SAMe) and SAMe and APAP treated
(SAMe + APAP). Values represent mean ± S.E.M., n = 4–6 mice per group. Total
hepatic GSH levels were measured 2 and 4 hours after injection (i.p.) of 500
mg/kg APAP. Groups with an asterisk (*) are statistically different (p < 0.05).
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FIGURE 14. Total hepatic glutathione levels following APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 500 mg/kg
treated (APAP), SAMe 500 mg/kg treated (SAMe) and SAMe and APAP treated
(SAMe + APAP). Values represent mean ± S.E.M., n = 4–6 mice per group. Total
hepatic glutathione levels were measured 2 and 4 hours after injection (i.p.) of
500 mg/kg APAP. Groups with unlike superscripts are statistically different.
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4.2.2. APAP Toxicity in Fasted Mice
Effect of 500 mg/kg SAMe just prior to 400 mg/kg APAP dose
For these studies, the animals were randomly divided into four treatment
groups, as shown in Table 1. The animals were fasted overnight (1700 – 0900
h), but had free access to water. The “VEH” group was dosed with water, the
“SAMe” group was administered with 500 mg/kg SAMe, the third group, “APAP”,
was injected with 400 mg/kg APAP and the final group (SAMe + APAP) received
500 mg/kg SAMe just prior to 400 mg/kg APAP. Mice were anesthetized and
livers were removed 1 hour post-APAP.
APAP-induced hepatotoxicity was reduced by the SAMe pretreatment.
APAP induced hepatic toxicity was confirmed by increased liver weight and
elevated plasma ALT levels when compared to VEH. Liver weight was increased
in animals dosed with APAP within 1 hour when compared to the VEH group
(TABLE 4). SAMe pretreatment doses prevented the increase in liver weight.
APAP increased plasma ALT levels (TABLE 5) above VEH values.

SAMe

prevented the APAP induced rise in plasma ALT levels.
There is no published data containing information about early effects of
APAP-induced hepatic toxicity. We were able to investigate some of the initial
effects of APAP-induced hepatotoxicity. Lipid peroxidation levels were unaltered
1 hour post-APAP (data not shown). This was most likely due to the short time
frame. GSH levels were severely depleted by APAP (FIGURE 15), but SAMe
was unable to significantly increase the GSH values. Once again, this was most
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likely due to the short time frame. Early on, damage is occurring at a rapid rate
and it is most likely that SAMe had not yet been able to relinquish all damaging
effects after 1 hour. These results also showed that fasting reduced total hepatic
GSH when compared to fed mice.

We knew from our previous study that

damage is seen as early as two hours. During the first hour of APAP toxicity,
APAP lyses cells causing the cell’s contents to flush into the liver resulting in a
rise in liver weight. We also showed GSH levels are depleted by almost 90%,
the toxicity initiates a rise in plasma ALT levels that continually increased for at
least 4 hours (Valentovic et al., 2004) and damage begins to become evident
around the centrilobular region of the liver.
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Group

VEH
APAP
SAMe
SAMe + APAP

SAMe dose
(mg/kg)
0
0
500
500

Time post-APAP
treatment (h)
1
1
1
1

Body weight (g)

Liver weight
(g/10g body wt.)

17.6 ± 0.3a
18.6 ± 0.4
17.8 ± 0.5
17.4 ± 0.3

0.46 ± 0.01a
0.50 ± 0.01b
0.45 ± 0.01a
a
0.45 ± 0.01

TABLE 4. Body and liver weight following APAP administration.
APAP was administered as 400 mg/kg (15 ml/kg), i.p. SAMe was administered
as 500 mg/kg (5 ml/kg), i.p. Values are reported at mean ± SEM with n = 4-10
animals/group. Groups with different superscripts denote statistical difference (p
< 0.05) within each treatment experiment.
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Group

SAMe dose
(mg/kg)

Time
post-APAP
treatment (h)

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

1
1
1
1

ALT (U/l)

61 ± 9a
293 ± 86b
69 ± 20a
104 ± 15a

TABLE 5. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 400 mg/kg;
S-Adenosyl-L-methionine

(SAMe)

i.p.

injected

500

mg/kg;

SAMe

and

acetaminophen (SAMe + APAP). Unlike letters (a, b) indicate groups are different
(p < 0.05) from each other using a one way ANOVA and Tukey’s post hoc test.
Values represent mean ± S.E.M. with n = 4-10 per group.
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FIGURE 15. Total hepatic glutathione levels 1 hour post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 400 mg/kg
treated (APAP), SAMe treated (SAMe) and SAMe + APAP treated (SAMe +
APAP). Values represent mean ± S.E.M., n = 4–10 mice per group. Total hepatic
GSH levels were measured 1 hour after injection (i.p.) of 400 mg/kg APAP.
Groups with unlike superscripts are statistically different (p < 0.05).
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Effect of 500 mg/kg SAMe just prior to 300 mg/kg APAP dose
After receiving more consistent results for GSH levels and other
parameters of heptotoxicity, we decided to continue fasting all mice prior to
treatment with APAP or VEH. We had seen APAP induced hepatic toxicity with
doses of 500 mg/kg and 400 mg/kg. To establish a threshold of overdose in
C57Bl/6 mice, we decided to lower the injection to 300 mg/kg APAP. While we
did see favorable results with SAMe attenuating APAP at 400 and 500 mg/kg
APAP, it was decided to attempt a determination of the range of possibilities with
SAMe to attenuate less “extreme” damage. Stramentinoli et al. (1979) had used
710 mg/kg APAP but the parameter of measurement was death vs. survival.
Valentovic et al. (2004), Bray et al. (1992) and Carrasco et al. (2000) had used
250-500 mg/kg APAP, 500 mg/kg APAP and 400 mg/kg APAP respectively.
Valentovic et al. (2004) was the only study to not use death vs. survival as the
main measure of protection by SAMe.
Animals were randomly divided as described previously (TABLE 1). The
groups remained the same: VEH, SAMe, APAP and SAMe + APAP. Animals
were fasted overnight (1700 – 0900 h), but allowed free access to water. The
mice were anesthetized (CO2) and livers were excised 1, 2 and 4 hours postAPAP.
Pretreatment with SAMe just prior to APAP reduced APAP-induced
hepatotoxicity. APAP hepatic toxicity was confirmed at 1, 2, and 4 hours postAPAP by increased liver weight (TABLE 6), elevated plasma ALT levels (TABLE
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7) and histological alterations (at 1 and 2 hours post-APAP injection) (FIGURE
16 and FIGURE 17 respectively). At 1 and 2 hours post-APAP, plasma ALT
values were not statistically higher than the control animals, but the trend was
leading toward increases in plasma ALT levels. This finding was confirmed at 4
hours post-APAP when animals dosed with APAP produced a statistically
significant higher plasma ALT level than the other treatment groups.
As expected, 1 hour post-APAP showed the least amount of damage. At
4 hours post-APAP, plasma ALT levels were highly elevated (over 8,000
Units/liter) and the liver weight showed a statistically significant raise. SAMe was
able to prevent a rise in liver weight and decreased plasma ALT values at all time
periods.
GSH levels were markedly diminished within 1 hour after APAP injection
when compared to VEH group (FIGURE 18).

GSH levels continued to be

severely diminished in the APAP group at 2 and 4 hours post-APAP (FIGURE 19
and FIGURE 20 respectively). SAMe administration did not alter baseline GSH
levels at 1, 2, or 4 hours post-liver excision.

However, SAMe was able to

increase GSH levels at all time frames measured when given just prior to APAP
as compared to groups given only APAP. The largest gain in GSH stores was
seen 4 hours post-APAP (FIGURE 21).
Oxidative stress measurements were only conducted at 4 hours postAPAP due to the lack of serious damage seen at 1 and 2 hours post-APAP.
Measurements of oxidative stress caused by APAP overdose were shown by
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increased protein carbonyl levels at 4 hours post-APAP of proteins between 37.1
– 67.2 kDa (FIGURE 22). There was no significant oxidative stress illustrated by
these procedures at 1 or 2 hours post-APAP (data not shown).
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Group

SAMe dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g)

Liver weight
(g/10g body wt.)

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

1
1
1
1

18.2 ± 0.5
18.2 ± 0.5
19.0 ± 0.5
19.6 ± 0.6

0.47 ± 0.01a
0.51 ± 0.01b
0.50 ± 0.01a
a
0.48 ± 0.01

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

2
2
2
2

17.6 ± 0.4
17.8 ± 0.5
18.0 ± 0.6
18.4 ± 0.4

0.49 ± 0.01
b
0.57 ± 0.02
a
0.49 ± 0.01
a
0.52 ± 0.02

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

18.0 ± 0.30
17.8 ± 0.36
18.0 ± 0.30
17.8 ± 0.36

0.51 ± 0.01
b
0.59 ± 0.01
a
0.51 ± 0.01
a
0.52 ± 0.02

a

a

TABLE 6. Body and liver weight following APAP administration.
APAP was administered as 300 mg/kg (15 ml/kg), i.p. SAMe was administered
as 500 mg/kg (5 ml/kg), i.p. Values are reported at mean ± SEM with n = 4-10
animals/group. Groups with different superscripts denote statistical difference (p
< 0.05) within each treatment experiment.
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Group

SAMe dose
(mg/kg)

Time
post-APAP
treatment (h)

ALT (U/l)

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

1
1
1
1

63 ± 18
243 ± 76
143 ± 41
143 ± 46

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

2
2
2
2

290 ± 79
647 ± 367
235 ± 57
369 ± 115

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

81 ± 19a
8533 ± 623b
373 ± 70a
2811 ± 346c

TABLE 7. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 300 mg/kg;
S-Adenosyl-L-methionine

(SAMe)

i.p.

injected

300

mg/kg;

SAMe

and

acetaminophen (SAMe + APAP) at doses listed for individual agents. Unlike
letters (a, b) indicate groups are different (p < 0.05) from each other using a one
way ANOVA and Tukey’s post hoc test. There was no statistical difference seen
at 1 or 2 hours post APAP administration. Values represent mean ± S.E.M. with
n = 4-10 per group.
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A
Central Vein

B

C
68

Central Vein

D
FIGURE 16. Histological examination 1 hour after APAP injection.
Hepatic tissues were prepared and stained with H&E. Representative slides of
(A)VEH; (B) SAMe pretreated; (C) 1 hour post-APAP injection and (D) mice
treated with SAMe just prior to APAP. Normal morphology was noted in the VEH
and SAMe animals. Damage was noted around the centrilobular region (pointed
out in slide C) in the APAP group. Magnification is 200×.
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A

Central Vein

B

C
70

Central Vein

D
FIGURE 17. Histological examination 2 hours after APAP injection.
Hepatic tissues were prepared and stained with H&E. Representative slides of
(A)VEH; (B) SAMe pretreated; (C) 2 hours post-APAP injection and (D) mice
treated with SAMe just prior to APAP. Normal morphology was noted in the VEH
and SAMe animals. Moderate damage was noted in the APAP group around the
central vein and is denoted with black arrows. Magnification is 200×.

71

5000

GSH (nmol/g tissue)
GSH (umol/g tissue)

4000

VEH
SAMe
APAP
SAMe + APAP

a

a

3000

2000

1000
b

c

0

1 HR

FIGURE 18. Total hepatic glutathione levels 1 hour post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 300 mg/kg
treated (APAP), SAMe 500 mg/kg treated (SAMe) and SAMe + APAP treated
(SAMe + APAP). Values represent mean ± S.E.M., n = 4–6 mice per group. Total
hepatic GSH levels were measured 1 hour after injection (i.p.) of 500 mg/kg
APAP. Groups with unlike superscripts are statistically different.
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FIGURE 19. Total hepatic glutathione levels 2 hours post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 300 mg/kg
treated (APAP), SAMe 500 mg/kg treated (SAMe) and SAMe + APAP treated
(SAMe + APAP). Values represent mean ± S.E.M., n = 4–6 mice per group. Total
hepatic GSH levels were measured 2 hours after injection (i.p.) of 500 mg/kg
APAP. Groups with unlike superscripts are statistically different.

73

4000
VEH
SAMe
APAP
SAMe+APAP

GSH (nmol/g tissue)
GSH (umol/g tissue)

a

3000

a

2000

1000

c

b

0

4 HR

FIGURE 20. Total hepatic glutathione levels 4 hours post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 300 mg/kg
treated (APAP), SAMe 500 mg/kg treated (SAMe) and SAMe + APAP treated
(SAMe + APAP). Values represent mean ± S.E.M., n = 4–6 mice per group. Total
hepatic GSH levels were measured 4 hours after injection (i.p.) of 500 mg/kg
APAP. Groups with unlike superscripts are statistically different.
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b†
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FIGURE 21. Total hepatic glutathione in APAP or SAMe + APAP dosed
groups 1, 2 or 4 hours post-APAP injection in C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 300 mg/kg
treated (APAP), SAMe 500 mg/kg treated (SAMe) and SAMe + APAP treated
(SAMe + APAP). Values represent mean ± S.E.M., n = 4–6 mice per group. Total
hepatic GSH levels were measured 1, 2 or 4 hours after injection (i.p.) of 500
mg/kg APAP. Groups with unlike superscripts are statistically different. The “†”
symbol depicts a statistically significant value (p < 0.05) when directly compared
to all other groups shown in the figure.
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S +A

APAP
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115.5 kDa
82.2 kDa
64.2 kDa
48.8 kDa
37.1 kDa

FIGURE 22. OxyBlot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1 VEH, Lane 2 SAMe, Lane 3 APAP and Lane 4
SAMe + APAP (S + A). SAMe was administered as 1.25 mmol/kg, i.p. (5 ml/kg).
APAP was injected i.p. at a dose of 300 mg/kg (15 ml/kg). VEH animals were
injected i.p. with water.
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Effect of 500 mg/kg SAMe just prior to 250 mg/kg APAP dose
For the final set of experiments using SAMe as a pretreatment, 250 mg/kg
APAP was used. We had already established APAP toxicity at 500, 400 and 300
mg/kg APAP in our laboratory as well as the successes of SAMe attenuating this
induced hepatic toxicity at 1, 2 and 4 hours post-APAP. At a dose of 250 mg/kg
APAP, the effect of SAMe during a minor overdose (as compared to 300 – 500
mg/kg) could be established.
The animals were randomly divided into four groups as previously
described and shown in Table 1. The animals were fasted overnight (1700-0900
h) with free access to water. SAMe was administered as a 500 mg/kg dose just
prior to 250 mg/kg APAP. Animals were anesthetized in a CO2 chamber and
livers were excised 2 and 4 hours post-APAP injection.
APAP-induced hepatotoxicity was reduced by the SAMe pretreatment at
both 2 and 4 hours post-injection.

APAP hepatic toxicity was confirmed by

increased liver weight and elevated plasma ALT values 2 and 4 hours post APAP
injection. APAP increased liver weight within 2 hours when compared to the
VEH group (TABLE 8). At 4 hours post-APAP, liver values were statistically
different when compared to VEH.

SAMe administration just prior to APAP

prevented the rise in liver weight at both 2 and 4 hours post-APAP injection.
Plasma ALT levels were increased post-APAP at 2 and 4 hours (p < 0.05)
(TABLE 9). When administered alone, SAMe had no effect on liver weight or
plasma ALT values at 2 or 4 hours. SAMe pretreatment did prevent a rise in liver
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weight and plasma ALT values were lowered relative to animals only receiving
APAP.
Glutathione levels were markedly diminished at both 2 and 4 hours after
APAP injection when compared to the VEH group (FIGURES 23-25). When
SAMe was administered prior to APAP, GSH levels were higher when directly
compared to the animals dosed with only APAP.

Pretreatment with SAMe

provided the best protection, with regards to APAP-induced GSH depletion.
Oxidative effects of APAP on the liver were confirmed with Western blots
at 2 and 4 hours post-APAP injection (FIGURES 26 and FIGURE 27
respectively).

Protein carbonyl levels (FIGURE 27) as well as 4HNE values

(FIGURE 28) were higher (p < 0.05) in animals dosed with 250 mg/kg APAP at 4
hours post injection relative to the control animals.

At 2 hours post-APAP,

protein carbonyl levels were higher in animals given only APAP. Given as a
predose, SAMe was able to prevent the rise (p < 0.05) in oxidized proteins as
well as protein carbonyls. SAMe, when given alone, had no significant effect on
oxidation when directly compared to VEH.
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Group

SAMe dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g)

Liver weight
(g/10g body wt.)

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

2
2
2
2

19.5 ± 0.6
18.2 ± 0.1
18.9 ± 0.5
18.3 ± 0.4

0.47 ± 0.02a
0.57 ± 0.01b
0.49 ± 0.01a
a
0.49 ± 0.02

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

20.0 ± 0.5
19.8 ± 0.7
19.4 ± 0.4
20.8 ± 0.4

0.47 ± 0.01
b
0.57 ± 0.01
a
0.49 ± 0.01
a
0.51 ± 0.01

a

TABLE 8. Body and liver weight following APAP administration.
APAP was administered as 250 mg/kg (15 ml/kg), i.p. SAMe was administered
as 500 mg/kg (5 ml/kg), i.p. Values are reported at mean ± SEM with n = 4-10
animals/group. Groups with different superscripts denote statistical difference (p
< 0.05) within each treatment experiment.
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Group

SAMe dose
(mg/kg)

Time
post-APAP
treatment (h)

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

2
2
2
2

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

ALT (U/l)

34 ± 10a
982 ± 120b
223 ± 81a
348 ± 66a
96 ± 25a
10630 ± 1057b
125 ± 20a
4675 ± 1223c

TABLE 9. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 250 mg/kg;
S-Adenosyl-L-methionine

(SAMe)

i.p.

injected

500

mg/kg;

SAMe

and

acetaminophen (SAMe + APAP) at doses listed for individual agents. Unlike
letters (a, b) indicate groups are different (p < 0.05) from each other using a one
way ANOVA and Tukey’s post hoc test. Values represent mean ± S.E.M. with n
= 4-10 per group.
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FIGURE 23. Total hepatic glutathione levels 2 hours post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 250 mg/kg
treated (APAP), SAMe 500 mg/kg treated (SAMe) and SAMe + APAP treated
(SAMe + APAP). Values represent mean ± S.E.M., n = 4–10 mice per group.
Total hepatic GSH levels were measured 2 hours after injection (i.p.) of 250
mg/kg APAP. Groups with unlike superscripts are statistically different.

81

300

b

GSH (nmol/g tissue)
GSH (umol/g tissue)

250

200

APAP
SAMe+APAP

a

150

100

50

0

2 HR

FIGURE 24. Total hepatic glutathione levels 2 hours post-APAP injection in
C57Bl/6 mice injected with APAP or SAMe just prior to APAP.
Represents direct comparison of GSH levels in animals dosed with 250 mg/kg
APAP or 500 mg/kg SAMe just prior to 250 mg/kg APAP. Values represent
mean ± S.E.M., n = 4–10 mice per group. Total hepatic GSH levels were
measured 2 hours after injection (i.p.) of 250 mg/kg APAP. Groups with unlike
superscripts are statistically different.
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FIGURE 25. Total hepatic glutathione levels 4 hours post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 250 mg/kg
treated (APAP), SAMe 500 mg/kg treated (SAMe) and SAMe + APAP treated
(SAMe + APAP). Values represent mean ± S.E.M., n = 4–10 mice per group.
Total hepatic GSH levels were measured 4 hours after injection (i.p.) of 250
mg/kg APAP. Groups with unlike superscripts are statistically different.
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S+A

APAP

SAMe

VEH

64.2 kDa
48.8 kDa

FIGURE 26. OxyBlot of samples 2 hours post-APAP injection.
Lanes are denoted as: Lane 1 vehicle, Lane 2 SAMe, Lane 3 acetaminophen,
Lane 4 SAMe prior to acetaminophen (S + A). SAMe was administered as 500
mg/kg, i.p. (5 ml/kg). APAP was injected i.p. at a dose of 250 mg/kg (15 ml/kg).
VEH animals were injected i.p. with water (15 ml/kg).
represents area of greatest differences.
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Highlighted region

S+A

APAP

SAMe

VEH

115.5 kDa
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FIGURE 27. OxyBlot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1 vehicle, Lane 2 SAMe, Lane 3 acetaminophen,
Lane 4 SAMe prior to acetaminophen (S + A). SAMe was administered as 500
mg/kg, i.p. (5 ml/kg). APAP was injected i.p. at a dose of 250 mg/kg (15 ml/kg).
VEH animals were injected i.p. with water (15 ml/kg).
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S+A

APAP

SAMe

VEH
115.5 kDa
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48.8 kDa
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FIGURE 28. 4HNE Blot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1 vehicle, Lane 2 SAMe, Lane 3 acetaminophen,
Lane 4 SAMe prior to acetaminophen (S + A). SAMe was administered as 500
mg/kg, i.p. (5 ml/kg). APAP was injected i.p. at a dose of 250 mg/kg (15 ml/kg).
VEH animals were injected i.p. with water (15 ml/kg).
represents area of greatest differences.
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Highlighted region

Effect of 204 mg/kg NAC just prior to 300 mg/kg APAP dose
Studies were conducted using the current clinical antidote, NAC, for APAP
overdose in order to directly compare the benefits of NAC vs. SAMe. Animals
were randomly divided into four treatment groups (TABLE 10): control treated
(VEH), APAP treated (APAP), NAC treated (NAC) and NAC pretreatment just
prior to APAP (NAC + APAP). NAC was administered at a dose of 204 mg/kg
(the exact same mmol concentration [1.25 mmol/kg] of SAMe that was given in
previous studies).

Animals were fasted overnight (1700 – 0900 h) with free

access to water, and livers were excised 1 or 4 hours post-APAP injection.
When given alone, NAC had no effect on liver weight, plasma ALT levels
or histological alterations when directly compared to the VEH. APAP hepatic
toxicity was confirmed by increased liver weight (TABLE 11), and elevated
plasma ALT levels (TABLE 12). APAP-induced hepatotoxicity was not prevented
when NAC was administered just prior to APAP when toxicity was elevated 1 or 4
hours after APAP injection.

NAC did not prevent increases in liver weight

(TABLE 11), damage to the centrilobular region 4 hours post-APAP (FIGURE 29)
nor did it prevent rises in plasma ALT values (TABLE 12).
GSH levels were diminished in groups dosed with APAP only at 1 hour
post-APAP injection (FIGURE 30). There was a gradual trend for increase in
total GSH in groups given NAC just prior to APAP at both 1 (FIGURE 30) and 4
(FIGURE 31) hours, but unlike animals dosed with SAMe just prior to APAP,
these values failed to produce statistically significant results.
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Oxidative stress in animals dosed with APAP was confirmed with an
increase in protein carbonyls near 48.8 kDa (FIGURE 32) and 4HNE values
mainly between 65 – 115 kDa (FIGURE 33) 4 hours post-APAP injection. There
is no measurable oxidative damage in our animal model 1 hour post-APAP (data
not shown). NAC, when given just prior to APAP, was unable to prevent a rise in
protein carbonyls or 4HNE values as illustrated by the Western blots. When
directly compared to the VEH, NAC had no significant effect on the production of
oxidized protein or protein carbonyls.
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Group
VEH
APAP
NAC
NAC + APAP

APAP
No
Yes
No
Yes

NAC
No
No
Yes
Yes

TABLE 10. NAC and APAP treatment regimens.

Group

NAC dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g)

Liver weight
(g/10g body wt.)

VEH
APAP
NAC
NAC + APAP

0
0
204
204

1
1
1
1

16.8 ± 0.5
16.8 ± 0.5
17.6 ± 0.7
17.2 ± 0.5

0.50 ± 0.02
0.53 ± 0.02
0.50 ± 0.01
0.50 ± 0.02

VEH
APAP
NAC
NAC + APAP

0
0
204
204

4
4
4
4

17.6 ± 0.4
18.4 ± 0.8
18.0 ± 0.6
18.2 ± 0.4

0.46 ± 0.02a
0.58 ± 0.01b
a
0.50 ± 0.01
0.58 ± 0.01b

TABLE 11. Body and liver weight following APAP administration.
APAP was administered as 300 mg/kg (15 ml/kg), i.p. NAC was administered as
204 mg/kg (5 ml/kg), i.p. Values are reported at mean ± SEM with n = 4-5
animals/group. Groups with different superscripts denote statistical difference (p
< 0.05) within each treatment experiment.
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Group

NAC dose
(mg/kg)

Time
post-APAP
treatment (h)

ALT (U/l)

VEH
APAP
NAC
NAC + APAP

0
0
204
204

1
1
1
1

35 ± 13
266 ± 92
124 ± 43
116 ± 30

VEH
APAP
NAC
NAC + APAP

0
0
204
204

4
4
4
4

84 ± 19a
9147 ± 468b
108 ± 30a
10421 ± 1125b

TABLE 12. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 300 mg/kg;
N-acetylcysteine (NAC) i.p. injected 204 mg/kg; NAC and acetaminophen (NAC +
APAP) at doses listed for individual agents. Unlike letters (a, b) indicate groups
are different (p < 0.05) from each other using a one way ANOVA and Tukey’s
post hoc test. There was no statistical difference seen regarding plasma ALT
values 1 hour post-injection. Values represent mean ± S.E.M. with n = 4-5 per
group.
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FIGURE 29. Histological examination of NAC given just prior to APAP 2
hours post-APAP injection.
Necrosis still evident around central vein area. Some protection seen, but areas
of damage are more evident than when compared to animals given SAMe just
prior to APAP. Areas of damage around centrilobular region shown by black
arrow.
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FIGURE 30. Total hepatic glutathione levels 1 hour post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 300 mg/kg
treated (APAP), NAC 204 mg/kg treated (NAC) and NAC + APAP treated (NAC +
APAP). Values represent mean ± S.E.M., n = 4–10 mice per group. Total hepatic
GSH levels were measured 1 hour after injection (i.p.) of 300 mg/kg APAP.
Groups with unlike superscripts are statistically different.
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FIGURE 31. Total hepatic glutathione levels 4 hours post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen 300 mg/kg
treated (APAP), NAC 204 mg/kg treated (NAC) and NAC + APAP treated (NAC +
APAP). Values represent mean ± S.E.M., n = 4–10 mice per group. Total hepatic
GSH levels were measured 4 hours after injection (i.p.) of 300 mg/kg APAP.
Groups with unlike superscripts are statistically different.
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N+A

APAP

NAC

VEH

82.2 kDa
64.2 kDa
48.8 kDa
37.1 kDa
25.9 kDa

FIGURE 32. OxyBlot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1 VEH, Lane 2 NAC, Lane 3 APAP, Lane 4 NAC
prior to APAP. NAC was administered as 204 mg/kg, i.p. (5 ml/kg). APAP was
injected i.p. at a dose of 300 mg/kg (15 ml/kg). VEH animals were injected i.p.
with water (15 ml/kg).
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FIGURE 33. 4HNE Blot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lanes 1-2 VEH, Lanes 3-4 NAC, Lane 5-6 APAP, Lane
7-8 NAC prior to APAP (N + A). NAC was administered as 204 mg/kg, i.p. (5
ml/kg). APAP was injected i.p. at a dose of 300 mg/kg (15 ml/kg). VEH animals
were injected i.p. with water (15 ml/kg). Highlighted region represents area of
greatest differences.
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Effect of 500 mg/kg SAMe just prior to 1000 mg/kg DEM
Diethyl maleate (DEM) and buthionine sulfoximine are GSH depleting
agents.

Both inhibit GSH already in the body.

Once inhibited, the GSH is

incapable of providing any type of antioxidant support (Casey et al., 2002;
Hosoya et al., 2002). However new GSH can be produced in the presence of
DEM since DEM binds directly to the GSH compound. Buthionine sulfoximine,
on the other hand, will prohibit production of new GSH by selectively inhibiting γglutamylcysteine synthetase, the rate-limiting enzyme in the synthesis of new
GSH (Anderson et al., 1999; Griffith and Meister, 1979; Griffith, 1982). This
experiment was designed to measure the efficiency of SAMe to produce GSH
using DEM to block the activity of pre-existing GSH. This study also evaluated
whether NAC and SAMe would have comparable effects on GSH.
Animals were divided into three treatment groups (TABLE 13): control
treated with corn oil (VEH), DEM treated (DEM) and SAMe treated just prior to
DEM (SAMe + DEM). The animals were fasted overnight (1700 – 0900 h) but
were allowed free access to water. The following day, the animals were injected
(i.p.) with SAMe and/or DEM. SAMe was administered in a dose of 500 mg/kg
and DEM was given at 1000 mg/kg. The mice were anesthetized in a CO2
chamber 2 and 4 hours post-DEM and livers were excised.
As expected, DEM had no effect on liver weight (TABLE 14). However,
GSH levels were severely depleted (p < 0.05) in animals dosed with only DEM at
both 2 and 4 hours (FIGURE 34 & FIGURE 35 respectively). When pretreated
with SAMe, GSH stores increased almost 50% (FIGURE 35) at 4 hours post96

DEM. There was no noticeable difference in GSH levels between DEM and
SAMe + DEM 2 hours post-DEM injection (FIGURE 34).
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Group
VEH
DEM
SAMe + DEM

DEM
No
Yes
Yes

SAMe
No
No
Yes

TABLE 13. SAMe and DEM treatment regimens.

Group

SAMe dose
(mg/kg)

Time post-DEM
treatment (h)

Body weight (g)

Liver weight
(g/10g body wt.)

VEH
DEM
SAMe + DEM

0
500
500

2
2
2

21.4 ± 0.5
21.6 ± 1.0
22.0 ± 0.7

0.46 ± 0.01
0.45 ± 0.02
0.45 ± 0.01

VEH
DEM
SAMe + DEM

0
500
500

4
4
4

23.2 ± 0.8
24.4 ± 0.7
24.0 ± 0.0

0.42 ± 0.01
0.41 ± 0.01
0.44 ± 0.01

TABLE 14. Body and liver weight following DEM administration.
DEM was administered as 1000 mg/kg, i.p. SAMe was administered as 500
mg/kg (5 ml/kg), i.p.

Values are reported as mean ± SEM with n = 4-10

animals/group. Groups with different superscripts denote statistical difference (p
< 0.05) within each treatment experiment.
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FIGURE 34. Total hepatic glutathione levels 2 hours post-DEM injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), DEM treated (DEM) and
SAMe + DEM treated (SAMe + DEM). Values represent mean ± S.E.M., n = 4–10
mice per group. Total hepatic GSH levels were measured 2 hours after injection
(i.p.) of 1000 mg/kg DEM. Groups with unlike superscripts are statistically
different.
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FIGURE 35. Total hepatic glutathione levels 4 hours post-DEM injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), DEM treated (DEM) and
SAMe + DEM treated (SAMe + DEM). Values represent mean ± S.E.M., n = 4–10
mice per group. Total hepatic GSH levels were measured 4 hours after injection
(i.p.) of 1000 mg/kg DEM. Groups with unlike superscripts are statistically
different.
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Effect of 204 mg/kg NAC just prior to 1000 mg/kg DEM
Using the same mmol dose as SAMe (1.25 mmol/kg), NAC was
administered the same way as previously described. Animals were divided into
three treatment groups (TABLE 15): control treated with corn oil (VEH), DEM
treated (DEM) and NAC treated just prior to DEM (NAC + DEM). NAC was
administered in a dose of 204 mg/kg and DEM was given at 1000 mg/kg. The
animals were fasted overnight (1700 – 0900 h) but were allowed free access to
water. The following day, the animals were injected (i.p.) with NAC and/or DEM.
The mice were anesthetized in a CO2 chamber 2 and 4 hours post-DEM and
livers were excised.
Similar to the SAMe studies, DEM had no effect on liver weight at 2 or 4
hours post-injection (TABLE 16). However, GSH levels were severely depleted
(p < 0.05) at both 2 (FIGURE 36) and 4 (FIGURE 37) hours. When pretreated
with NAC, GSH stores were similar between DEM and DEM + NAC 2 hours postDEM (FIGURE 36). However at 4 hours, the increase of GSH stores when NAC
was administered just prior to DEM was less noticeable when directly compared
to SAMe + DEM GSH levels (FIGURE 37).

DEM inhibited GSH levels, but

neither NAC nor SAMe altered GSH levels when measured 2 hours after DEM
treatment. However, GSH levels with SAMe provided better protection when
monitored 4 hours after DEM injection. These results suggest that SAMe is more
potent than NAC at producing new GSH.
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Group
VEH
DEM
NAC + DEM

DEM
No
Yes
Yes

NAC
No
No
Yes

TABLE 15. NAC and DEM treatment regimens.

Group

NAC dose
(mg/kg)

Time post-DEM
treatment (h)

Body weight (g)

Liver weight
(g/10g body wt.)

VEH
DEM
NAC + DEM

0
204
204

2
2
2

23.6 ± 0.7
24.4 ± 0.7
22.4 ± 0.7

0.42 ± 0.01
0.40 ± 0.0
0.42 ± 0.01

VEH
DEM
NAC + DEM

0
204
204

4
4
4

22.8 ± 0.8
23.6 ± 0.4
22.8 ± 0.5

0.42 ± 0.01
0.41 ± 0.01
0.43 ± 0.01

TABLE 16. Body and liver weight following DEM administration.
DEM was administered as 1000 mg/kg, i.p.
mg/kg (5 ml/kg), i.p.

NAC was administered as 204

Values are reported as mean ± SEM with n = 4-10

animals/group. Groups with different superscripts denote statistical difference (p
< 0.05) within each treatment experiment.
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FIGURE 36. Total hepatic glutathione levels 2 hours post-DEM injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), DEM treated (DEM) and NAC
+ DEM treated (NAC + DEM). Values represent mean ± S.E.M., n = 4–10 mice
per group. Total hepatic GSH levels were measured 2 hours after injection (i.p.)
of 1000 mg/kg DEM. Groups with unlike superscripts are statistically different.
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FIGURE 37. Total hepatic glutathione levels 4 hours post-DEM injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), DEM treated (DEM) and NAC
+ DEM treated (NAC + DEM). Values represent mean ± S.E.M., n = 4–10 mice
per group. Total hepatic GSH levels were measured 4 hours after injection (i.p.)
of 1000 mg/kg DEM. Groups with unlike superscripts are statistically different.
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Effect of 250 mg/kg SAMe + 102 mg/kg NAC just prior to 300 mg/kg APAP dose
To investigate the possibility of synergistic effects when combining SAMe
+ NAC and to study the possibility of the two drugs working via different
mechanisms, a combination therapy cocktail was developed.

We wanted to

directly compare the therapeutic effects of the cocktail to the prior experiments
where SAMe or NAC were given individually.

Therefore, the total mmol

concentration had to equal that of prior experiments involving SAMe and NAC.
We used ½ of what we had normally been using for both SAMe and NAC: 250
mg/kg SAMe and 102 mg/kg NAC.
It is believed that the mechanism by which SAMe and NAC produce GSH
is very similar (FIGURE 38), but there is not agreement that this is the only
mechanism by which the two drugs elicit the protective effects seen. Both, SAMe
and NAC, can produce the rate limiting compound, cysteine, that is needed for
GSH production.
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FIGURE 38.

Diagrammatic representation of GSH production with both

SAMe and NAC.
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Animals were divided, just as before, into four treatment groups (TABLE
17): control treated (VEH), APAP treated with 1.98 mmol/kg (APAP), SAMe +
NAC treated with 0.625 mmol/kg of SAMe and NAC (SAMe + NAC) and SAMe +
NAC pretreatment just prior to APAP (SAMe + NAC+ APAP). Animals were
fasted overnight from 1700 – 0900 h, but allowed free access to water. At 0900
h the morning following fasting, the mice were injected i.p. with the specified
amount of water, SAMe + NAC, APAP or SAMe + NAC + APAP. At 1 and 4
hours post-APAP injection, the mice were anesthetized with CO2, blood was
drawn via cardiac puncture and the livers were removed.
APAP-induced hepatotoxicity was seen at 4 hours post-APAP injection.
liver weight (TABLE 18) and plasma ALT values (TABLE 19) were significantly (p
< 0.05) raised 4 hours after APAP had been injected. No severe toxicity was
seen 1 hour post-APAP.

The SAMe + NAC pretreatment at 4 hours post-

injection showed limited protection. Liver weight was decreased (TABLE 18)
when the SAMe + NAC cocktail was given just prior to APAP, but the protection
seen was not as great as when SAMe alone was given just prior to APAP. There
was no protection seen at 1 or 4 hours post-APAP with regards to the plasma
ALT values (TABLE 19).
GSH levels were markedly diminished at both 1 (FIGURE 39) and 4
(FIGURE 40) hours after APAP injection when compared to the VEH group.
When SAMe + NAC were administered prior to APAP, GSH levels were slightly
higher than the group dosed with APAP at both 1 and 4 hours post-APAP. There
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was no statistically significant difference in the groups given SAMe + NAC vs.
SAMe + NAC just prior to APAP at either time periods.
Oxidative effects of APAP on the liver were confirmed with lipid
peroxidation, protein carbonyl values and 4HNE adducted proteins 4 hours postAPAP (FIGURES 41-43 respectively). Oxidative stress was not seen 1 hour
post-APAP based on indicators such as protein carbonyls, etc. (data not shown).
While we did not see any significant protective effects with SAMe + NAC
attenuating damage done by APAP regarding decreased GSH levels, increases
in ALT levels and high liver weights, we did see strong effects of decreasing lipid
peroxidation levels when SAMe + NAC was given just prior to APAP and livers
were excised 4 hours post-injection (FIGURE 41).

However, the SAMe + NAC

cocktail did not protect against the production of APAP-induced protein carbonyls
or 4HNE adducted proteins (FIGURE 42 and FIGURE 43 respectively).
In summary, we did not see any protective effects of the pretreatment with
the ALT and GSH assays nor the liver weight values at 1 or 4 hours post-APAP
injection. SAMe + NAC pretreatment was also unable to prevent the amount of
protein carbonyls produced when given just prior to APAP. The only protective
effect that was seen with the cocktail was that SAMe + NAC did provide positive
results regarding prevention of TBAR production 4 hours post-APAP.

The

combination of SAMe + NAC at combined equimolar dose of 1.24 mmol/kg did
not provide better protection than SAMe.
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Group
VEH
APAP
SAMe + NAC
SAMe +NAC + APAP

APAP
No
Yes
No
Yes

SAMe + NAC
No
No
Yes
Yes

TABLE 17. SAME + NAC and APAP treatment regimens.

Group

SAMe/NAC dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g) Liver weight
(g/10g body wt.)

VEH
APAP
SAMe + NAC
SAMe + NAC + APAP

0
0
250/102
250/102

1
1
1
1

17.6 ± 0.4
16.0 ± 0.6
16.8 ± 0.5
16.8 ± 0.5

0.49 ± 0.02
0.51 ± 0.01
0.47 ± 0.02
0.50 ± 0.02

VEH
APAP
SAMe + NAC
SAMe + NAC + APAP

0
0
250/102
250/102

4
4
4
4

17.8 ± 0.4
17.6 ± 0.3
17.8 ± 0.4
18.0 ± 0.4

0.47 ± 0.01
b
0.59 ± 0.01
a
0.48 ± 0.01
c
0.53 ± 0.01

a

TABLE 18. Body and liver weight following APAP administration.
APAP was administered as 300 mg/kg (15 ml/kg), i.p. SAMe was administered
as 250 mg/kg, i.p. and NAC was administered as 102 mg/kg, i.p. Values are
reported as mean ± SEM with n = 4-10 animals/group. Groups with different
superscripts denote statistical difference (p < 0.05) within each treatment
experiment.
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Group

SAMe/NAC dose
(mg/kg)

Time
post-APAP
treatment (h)

ALT (U/l)

VEH
APAP
SAMe + NAC
SAMe + NAC + APAP

0
0
204
204

1
1
1
1

58 ± 31
62 ± 24
54 ± 22
125 ± 54

VEH
APAP
SAMe + NAC
SAMe + NAC + APAP

0
0
204
204

4
4
4
4

78 ± 26a
10671 ± 584b
80 ± 36a
10566 ± 1102b

TABLE 19. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 300 mg/kg;
SAMe i.p. injected 250 mg/kg + NAC injected i.p. 102 mg/kg (SAMe + NAC);
SAMe + NAC and acetaminophen (SAMe + NAC + APAP) at doses listed for
individual agents. Unlike letters (a, b) indicate groups are different (p < 0.05) from
each other using a one way ANOVA and Tukey’s post hoc test.
represent mean ± S.E.M. with n = 4-10 per group.
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FIGURE 39. Total hepatic glutathione levels 1 hour post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), SAMe 250 mg/kg + NAC 102 mg/kg treated (SAMe + NAC) and SAMe +
NAC + APAP treated (SAMe + NAC + APAP). Values represent mean ± S.E.M.,
n = 4–10 mice per group. Total hepatic GSH levels were measured 1 hour after
injection (i.p.) of 300 mg/kg APAP. Groups with unlike superscripts are
statistically different.
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FIGURE 40. Total hepatic glutathione levels 4 hours post-APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), SAMe 250 mg/kg + NAC 102 mg/kg treated (SAMe + NAC) and SAMe +
NAC + APAP treated (SAMe + NAC + APAP). Values represent mean ± S.E.M.,
n = 4–10 mice per group. Total hepatic GSH levels were measured 4 hours after
injection (i.p.) of 300 mg/kg APAP. Groups with unlike superscripts are
statistically different.
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FIGURE 41.

Lipid peroxidation levels 4 hours post-APAP injection in

C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), SAMe 250 mg/kg + NAC 102 mg/kg treated (SAMe + NAC) and SAMe +
NAC + APAP treated (SAMe + NAC + APAP). Values represent mean S.E.M., n
= 4–10 mice per group. Lipid peroxidation was measured 4 hours after injection
(i.p.) of 300 mg/kg APAP. Lipid peroxidation was measured as µmol
malondialdehyde (MDA)/mg protein. Group denoted with an asterisk (*) are
statistically different.
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FIGURE 42. OxyBlot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1 vehicle, Lane 2 SAMe + NAC (N + S), Lane 3
acetaminophen, Lane 4 SAMe + NAC prior to acetaminophen (N + S + A).
SAMe was administered as 250 mg/kg and NAC was given as 102 mg/kg, i.p.
APAP was injected i.p. at a dose of 300 mg/kg (15 ml/kg). VEH animals were
injected i.p. with water (15 ml/kg).
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FIGURE 43. 4HNE Blot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1-3 VEH, Lane 4-6 SAMe + NAC (N +S), Lane 7-9
APAP, Lane 10-12 SAMe + NAC prior to APAP (N + S + A). SAMe was
administered as 250 mg/kg and NAC was given as 102 mg/kg, i.p. APAP was
injected i.p. at a dose of 300 mg/kg (15 ml/kg). VEH animals were injected i.p.
with water (15 ml/kg).

Highlighted region represents area with greatest

differences.
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Positive Control: High dose of NAC
It is known that NAC can attenuate APAP-induced hepatic toxicity.
However in emergency situations, the doses of NAC that are given are quite
large. We have shown that on a similar mmol basis, NAC is unable to protect the
liver as effectively as SAMe. To disprove any hesitancies of the ability of NAC to
attenuate APAP-induced toxicity in our laboratory, we used a high amount of
NAC (1200 mg/kg) to show its protective effects. This dose is roughly 10 times
larger than our experiments directly comparing NAC vs. SAMe.
Animals were prepared as previously described. Twenty animals were
randomly divided into 4 groups consisting of a vehicle (VEH), NAC treated
(NAC), APAP treated (APAP) and NAC given just prior to APAP (NAC + APAP).
The animals were fasted from 1700-0900 h but allowed free access to water.
The following morning, animals (NAC and NAC + APAP) were injected at 0900 h
with NAC at a dose of 1200 mg/kg (5 ml/kg adjusted to pH 7). The APAP and
NAC + APAP groups were injected i.p. with 300 mg/kg APAP (15 ml/kg). The
VEH group was injected i.p. with water (15 ml/kg).

The animals were

anesthetized with CO2 4 hours after APAP injection (1300 h), blood was collected
via cardiac puncture and the livers were removed and placed in ice-cold Krebs
buffer.
As expected, the high dose of NAC provided protection in all of the
measurable parameters. APAP caused increased liver weight (TABLE 20), large
increases in plasma ALT values (TABLE 21) and histological alterations
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(FIGURE 44). NAC, when given at the 1200 mg/kg dose, was able to prevent
the rise in liver weights and plasma ALT values, plus reverse the damage around
the centrilobular region of the liver.
GSH levels were markedly diminished at 4 hours after APAP injection
when compared to the VEH group (FIGURE 45). When the high dose of NAC
was administered prior to APAP, GSH levels were markedly higher than the
group dosed with APAP 4 hours post-injection. There was statistically significant
difference in the groups given NAC vs. NAC just prior to APAP.
Further protection was illustrated by the ability of the high dose of NAC to
attenuate oxidative stress measured by the production of 4HNE adducted
proteins (FIGURE 46).

The 4HNE gel showed a lower concentration of the

amount of oxidized proteins in the NAC + APAP animals compared to the APAP
dosed animals. The high dose of NAC showed no effect on the production of
4HNE adducted proteins when directly compared to the VEH group.
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Group

NAC dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g) Liver weight
(g/10g body wt.)

VEH
APAP
NAC
NAC + APAP

0
0
1200
1200

4
4
4
4

19.6 ± 0.4
17.6 ± 0.4
18.4 ± 0.7
19.5 ± 0.5

a

0.46 ± 0.01
b
0.56 ± 0.01
a
0.49 ± 0.01
a
0.50 ± 0.01

TABLE 20. Body and liver weight following APAP administration.
APAP was administered as 300 mg/kg (15 ml/kg), i.p. NAC was administered as
1200 mg/kg (5 ml/kg), i.p. Values are reported at mean ± SEM with n = 4-10
animals/group. Groups with different superscripts denote statistical difference (p
< 0.05) within each treatment experiment.

Group

NAC dose
(mg/kg)

Time
post-APAP
treatment (h)

ALT (U/l)

VEH
APAP
NAC
NAC + APAP

0
0
1200
1200

4
4
4
4

34 ± 13a
6674 ± 1377b
108 ± 52a
a
606 ± 215

TABLE 21. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 300 mg/kg;
NAC i.p. injected 1200 mg/kg (NAC); NAC and acetaminophen (NAC + APAP) at
doses listed for individual agents. Unlike letters (a, b) indicate groups are
different (p < 0.05) from each other using a one way ANOVA and Tukey’s post
hoc test. Values represent mean ± S.E.M. with n = 4-5 per group.
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FIGURE 44. Histological examination 4 hours after APAP injection.
Hepatic tissues were prepared and stained with H&E. Representative slides of
(A) vehicle (VEH); (B) NAC (1200 mg/kg) treated; (C) 4 hours postacetaminophen (APAP) injection and (D) mice treated with NAC just prior to
APAP.

Normal morphology was noted in the VEH, NAC and NAC + APAP

animals. Centrilobular damage was noted in the APAP group as shown by the
arrows in slide C. Magnification is 200×.
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FIGURE 45. Total hepatic glutathione levels following APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), NAC 1200 mg/kg treated (NAC) and NAC + APAP treated (NAC +
APAP). Values represent mean ± S.E.M., n = 4–5 mice per group. Total hepatic
GSH levels were measured 4 hours after injection (i.p.) of 300 mg/kg APAP. An
asterisk (*) marks statistically significant difference (p < 0.05) from the rest of the
treatment groups.
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FIGURE 46. 4HNE Blot with high dose of NAC.
Lanes are denoted as:

Lane 1-3 vehicle, Lane 4-6 NAC, Lane 7-8

acetaminophen, Lane 9-11 NAC + acetaminophen. NAC was administered as
1200 mg/kg. APAP was injected i.p. at a dose of 300 mg/kg (15 ml/kg). VEH
animals were injected i.p. with water (15 ml/kg).
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Effect of 3.84 mg/kg vitamin B6 + 500 mg/kg SAMe just prior to 300 mg/kg APAP
According to Lu (1998), vitamin B6 is a rate limiting agent in the production
of SAMe → GSH (FIGURE 4). If vitamin B6 were in short supply during APAP
overdose, it is possible that the mechanism would be halted at the production of
homocysteine. As described earlier, if the ratio of SAH:SAMe favors SAH, the
reaction will be reversed and no GSH will be produced. To further investigate the
mechanistic properties of SAMe and to discover if vitamin B6 could provide
additional therapeutic effects as compared to SAMe alone, we injected (i.p.) the
animals with a dose of vitamin B6 with SAMe just prior to APAP. The dose of
vitamin B6 that was used was comparable to a human’s recommended daily
allowance.
Animals were divided, just as before, into four treatment groups (TABLE
22): control treated (VEH), APAP treated (APAP), SAMe + vitamin B6 treated
(SAMe + vitamin B6) and SAMe + vitamin B6 pretreatment just prior to APAP
(SAMe + vitamin B6 + APAP). Vitamin B6 was administered in a dose of 3.84
mg/kg, SAMe was dosed at 500 mg/kg and APAP was injected (i.p.) 300 mg/kg.
The animals were fasted overnight (1700 – 0900 h) but were allowed free access
to water. The following day, the animals were anesthetized in a CO2 chamber 1
and 4 hours post-APAP and livers were excised.
APAP hepatic toxicity was confirmed by increased liver weight (only at 4
hours post-APAP injection) (TABLE 23) and elevated plasma ALT levels (TABLE
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24) at 4 hours post-APAP. One hour post-APAP showed change in plasma ALT
levels but not in the liver weight.
APAP-induced hepatotoxicity was prevented, to an extent, when vitamin
B6 was administered with SAMe just prior to APAP 4 hours post-injection. The
treatment prevented increases in liver weight and it prevented extreme rises in
plasma ALT values. However, 1 hour post-APAP the treatment showed virtually
no protection.

When directly comparing the benefits seen with vitamin B6 +

SAMe to the benefits of SAMe when given alone, there is either no difference or
SAMe works better by itself.
GSH levels were diminished in groups dosed with APAP at 1 and 4 hours
post-APAP injection (FIGURE 47 and FIGURE 48 respectively). There was a
gradual trend for increase in total GSH in groups given vitamin B6 + SAMe just
prior to APAP at both 1 and 4 hours, but only the values at 4 hours post-APAP
produced statistically significant results (FIGURES 48 and 49). There was a drop
in GSH levels in the group given vitamin B6 + SAMe only when directly compared
to the VEH group 4 hours post-injection.
Oxidative stress in animals dosed with APAP only was confirmed with an
increase in lipid peroxidation (FIGURE 50). The vitamin B6 + SAMe predose was
able to prevent a rise in lipid peroxidation at 4 hours post-APAP. There was no
notable difference in lipid peroxidation levels 1 hour post-APAP injection (data
not shown).
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Group
VEH
APAP
SAMe + Vitamin B6
SAMe +Vitamin B6 + APAP

APAP
No
Yes
No
Yes

SAMe + Vitamin B6
No
No
Yes
Yes

TABLE 22. SAMe + Vitamin B6 and APAP treatment regimens.

Group

SAMe/Vitamin B6
dose (mg/kg)

Time post-APAP
treatment (h)

Body weight (g) Liver weight
(g/10g body wt.)

VEH
APAP
SAMe + Vitamin B6
SAMe + Vitamin B6 + APAP

0
0
500/3.84
500/3.84

1
1
1
1

18.0 ± 0.0
17.6 ± 0.4
18.8 ± 0.5
17.2 ± 0.5

0.48 ± 0.01
0.49 ± 0.02
0.49 ± 0.01
0.49 ± 0.01

VEH
APAP
SAMe + Vitamin B6
SAMe + Vitamin B6 + APAP

0
0
500/3.84
500/3.84

4
4
4
4

19.2 ± 0.5
19.0 ± 0.5
18.6 ± 0.5
19.6 ± 0.5

0.48 ± 0.01
b
0.57 ± 0.01
a
0.49 ± 0.01
a
0.50 ± 0.01

a

TABLE 23. Body and liver weight following APAP administration.
APAP was administered as 300 mg/kg (15 ml/kg), i.p. SAMe was administered
as 500 mg/kg (5 ml/kg) with 3.84 mg/kg vitamin B6, i.p. Values are reported as
mean ± SEM with n = 4-10 animals/group. Groups with different superscripts
denote statistical difference (p < 0.05) within each treatment experiment.
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Group

SAMe/Vitamin B6
dose (mg/kg)

Time
post-APAP
treatment (h)

VEH
APAP
SAMe + Vitamin B6
SAMe + Vitamin B6 + APAP

0
0
500/3.84
500/3.84

1
1
1
1

179 ± 80
237 ± 80a
131 ± 39a
503 ± 110b

VEH
APAP
SAMe + Vitamin B6
SAMe + Vitamin B6 + APAP

0
0
500/3.84
500/3.84

4
4
4
4

96 ± 39
b
7905 ± 148
a
233 ± 148
4311 ± 874c

ALT (U/l)

a

a

TABLE 24. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 300 mg/kg;
SAMe i.p. injected 500 mg/kg + vitamin B6 injected i.p. 3.84 mg/kg (SAMe +
Vitamin B6); SAMe + vitamin B6 and acetaminophen (SAMe + vitamin B6 +
APAP) at doses listed for individual agents. Unlike letters (a, b) indicate groups
are different (p < 0.05) from each other using a one way ANOVA and Tukey’s
post hoc test. Values represent mean ± S.E.M. with n = 4-10 per group.
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FIGURE 47. Total hepatic glutathione levels following APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), SAMe 500 mg/kg + vitamin B6 3.84 mg/kg treated (SAMe + Vitamin B6)
and SAMe + Vitamin B6 and APAP treated (SAMe + Vitamin B6 + APAP). Values
represent mean ± S.E.M., n = 4–10 mice per group. Total hepatic GSH levels
were measured 1 hour after injection (i.p.) of 300 mg/kg APAP. Groups with
unlike superscripts are statistically different.
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FIGURE 48. Total hepatic glutathione levels following APAP injection in
C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), SAMe 500 mg/kg + vitamin B6 3.84 mg/kg treated (SAMe + Vitamin B6)
and SAMe + Vitamin B6 and APAP treated (SAMe + Vitamin B6 + APAP). Values
represent mean ± S.E.M., n = 4–10 mice per group. Total hepatic GSH levels
were measured 4 hours after injection (i.p.) of 300 mg/kg APAP. Groups with
unlike superscripts are statistically different.
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FIGURE 49. Total hepatic glutathione levels following APAP injection in
C57Bl/6 mice dosed with APAP or SAMe + Vitamin B6 just prior to APAP.
Animals were randomly divided into acetaminophen treated (APAP) and SAMe +
Vitamin B6 and APAP treated (SAMe + Vitamin B6 + APAP). Values represent
mean ± S.E.M., n = 4–10 mice per group. Total hepatic GSH levels were
measured 4 hours after injection (i.p.) of 300 mg/kg APAP. An asterisk (*) marks
a statistically significant difference (p < 0.05).
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FIGURE 50. Lipid Peroxidation following APAP injection in C57Bl/6
mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), SAMe 500 mg/kg + Vitamin B6 treated (SAMe + Vitamin B6) and SAMe
+ Vitamin B6 and APAP treated (SAMe + Vitamin B6 + APAP). Values represent
mean S.E.M., n = 4–10 mice per group. Lipid peroxidation was measured 4 hours
after injection (i.p.) of 300 mg/kg APAP. Lipid peroxidation was measured as
µmol malondialdehyde (MDA)/mg protein. Groups with unlike superscripts are
statistically different.
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4.3 Treatments Post-APAP
Effect of 250 mg/kg APAP 1 hour prior to 500 mg/kg SAMe dose
After reviewing the initial results of the abilities of SAMe to attenuate
APAP-induced hepatotoxicity, the next step was to investigate the possibilities of
SAMe as an antidote to APAP overdose. This experiment enabled us to mimic
what occurs in the clinical setting since treatment is administered after
overdosing on APAP.

This experiment provided some of the most valuable

information regarding the possibility of SAMe as a true antidote to APAP-induced
hepatic toxicity.
Experiments were set up as before. Animals were randomly divided into 4
treatment groups with 5 animals per group (TABLE 25): control (VEH), APAP
(APAP), SAMe (SAMe) and APAP injected 1 hour prior to the administration of
SAMe (SAMe + APAP). Animals were fasted overnight from 1700 – 0900 h, but
had free access to water.

The following morning at 0900 h, animals were

injected with water or APAP. At 1000 h, the SAMe treatment was administered
i.p. to the SAMe + APAP group. Three hours later (4 hours post-APAP), the mice
were anesthetized with CO2, blood was collected via cardiac puncture and livers
were excised and placed on ice-cold Krebs buffer.
APAP-induced hepatotoxicity was reduced by the SAMe treatment. APAP
hepatic toxicity was confirmed by increased liver weight (TABLE 26), elevated
plasma ALT values (TABLE 27) and histological alterations of visible centrilobular
necrosis (FIGURE 51). APAP increased liver weight when directly compared to
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the VEH group. SAMe treatment doses prevented the increase in liver weight
attributed to APAP treatment. APAP increased (p < 0.05) plasma ALT levels
above VEH values 4 hours post-APAP injection.

SAMe injection post-APAP

prevented the dramatic APAP-induced rise in plasma ALT levels. These findings
support the possibility of SAMe as an antidote to APAP toxicity.
Examination by light microscopy showed normal morphology for the VEH
treated group. In the groups treated only with APAP, focal centrilobular changes
were observed (FIGURE 51). The SAMe and SAMe + APAP groups showed no
differences when directly compared to the VEH group. The SAMe + APAP group
showed no damage within the centrilobular region (FIGURES 51).
GSH levels were markedly diminished 4 hours after APAP injection when
compared to the VEH group (FIGURE 52). SAMe administration (500 mg/kg) did
not alter baseline GSH levels probably due to the ratio of SAH:SAMe levels.
Amazingly, the group that had been administered SAMe 1 hour after APAP
completely recovered GSH levels when compared to the VEH group (FIGURE
52). SAMe was able to replenish GSH lost within 3 hours of administration.
Results seen were better than when SAMe was given as a pretreatment to
APAP. Once again, this was most likely due to the mechanistic properties of
SAMe in the production of GSH. If SAH levels are favored (no GSH is needed),
the reaction is reversed and no GSH is produced. However if GSH levels are low
(as depicted in this experiment), then the reaction proceeds forward and GSH is
produced.
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Group
VEH
APAP
SAMe
SAMe + APAP

APAP
No
Yes
No
Yes

SAMe
No
No
Yes
Yes

TABLE 25. SAMe and APAP treatment regimens.
All injections were i.p. APAP and VEH were administered 0900 h. SAMe was
administered at 1000 h at a dose of 500 mg/kg.

Group

SAMe dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g) Liver weight
(g/10g body wt.)

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

16.4 ± 0.4
16.8 ± 0.4
17.0 ± 0.3
16.4 ± 0.3

a

0.47 ± 0.01
b
0.55 ± 0.01
a
0.47 ± 0.01
a
0.50 ± 0.01

TABLE 26. Body and liver weight following APAP administration.
APAP was administered as 250 mg/kg (15 ml/kg), i.p. 1 hour prior to SAMe (500
mg/kg (5 ml/kg), i.p.).

Statistical differences (p < 0.05) are denoted by

superscripts. Values are reported as mean ± SEM with n = 4-10 animals/group.
Groups with different superscripts denote statistical difference (p < 0.05) within
each treatment experiment.
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Group

SAMe dose
(mg/kg)

Time
post-APAP
treatment (h)

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

ALT (U/l)

96 ± 25a
12476 ± 407b
84 ± 16a
403 ± 107c

TABLE 27. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 250 mg/kg;
S-Adenosyl-L-methionine

(SAMe)

i.p.

injected

500

mg/kg;

SAMe

and

acetaminophen (SAMe + APAP) at doses listed for individual agents. Unlike
letters (a, b) indicate groups are different (p < 0.05) from each other using a one
way ANOVA and Tukey’s post hoc test. Values represent mean ± S.E.M. with n
= 4-10 per group.
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FIGURE 51. Histological examination 4 hours after APAP injection.
Hepatic tissues were prepared and stained with H&E. Representative slides of
(A)vehicle (VEH); (B) SAMe (500 mg/kg) treated; (C) 4 hours postacetaminophen (APAP) injection and (D) mice treated with SAMe 1 hour after
APAP. Normal morphology was noted in the VEH, SAMe and SAMe + APAP
animals. Moderate damage was noted in the APAP group around the
centrilobular region as shown by the arrows in slide C. Magnification is 200×.
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FIGURE 52.

SAMe antidote studies: Total hepatic glutathione levels 4

hours post-APAP injection in C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), SAMe 500 mg/kg treated (SAMe) and SAMe + APAP treated (SAMe +
APAP). Values represent mean ± S.E.M., n = 4–10 mice per group. Total hepatic
GSH levels were measured 4 hours after injection (i.p.) of 250 mg/kg APAP. An
asterisk (*) marks statistically significant difference (p < 0.05) from the rest of the
treatment groups.

137

Effect of 250 mg/kg APAP 1 hour prior to 204 mg/kg NAC dose
After reviewing the initial results of the abilities of SAMe to attenuate
APAP-induced hepatotoxicity and comparing that to results seen with NAC, we
wanted to test the abilities of SAMe vs. NAC in attenuating APAP-induced
hepatic toxicity. Since NAC is the main antidote of choice for APAP related
overdoses, we wanted to investigate the protective effects of NAC in mice and
directly compare the effects to SAMe. This experiment provided valuable data
regarding the possibility of SAMe vs. NAC as an effective antidote for hepatic
toxicity resulting from APAP overdose.
Animals were randomly divided into 4 treatment groups with 5 animals per
group (TABLE 28): control (VEH), APAP (APAP), NAC (NAC) and APAP treated
1 hour prior to the administration of NAC (NAC + APAP). Animals were fasted
overnight (1700 – 0900 h) and had free access to water. The following morning
at 0900 h, animals were injected with either water or APAP. At 1000 h, the NAC
treatment was administered i.p. to the NAC + APAP group. Three hours later (4
hours post-APAP), the mice were anesthetized with CO2, blood was collected via
cardiac puncture and livers were excised and stored on ice-cold Krebs buffer for
analysis.
APAP-induced hepatotoxicity was reduced by the NAC treatment, but not
to the same extent as the animals given SAMe. Just as before, APAP hepatic
toxicity was confirmed by increased liver weight, elevated plasma ALT values
and histological alterations.

APAP increased liver weight when directly
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compared to the VEH group (TABLE 29), but NAC treatment doses were not able
to prevent the increase in liver weight attributed to APAP. APAP increased (p <
0.05) plasma ALT levels (TABLE 30) above VEH 4 hours post-APAP injection.
NAC injection post-APAP minimally prevented APAP-induced rise in plasma ALT
levels.
Examination by light microscopy showed normal morphology for the VEH
treated group. In the groups treated only with APAP, focal centrilobular changes
were observed (FIGURE 53).

The NAC group showed no differences when

directly compared to the VEH group. The NAC + APAP group showed less
damage within the centrilobular region when compared to the APAP group.
However, there was less protection seen in the NAC + APAP group vs. the SAMe
+ APAP animal set.
GSH levels were markedly diminished after APAP injection when
compared to the VEH group (FIGURE 54). NAC administration did not alter
baseline GSH levels. This may in fact be due to similar reasons of why we don’t
see an increase in GSH levels when SAMe is administered. It is possible that if
there is not a necessity to produce more GSH, the reaction does not move
forward. Instead, the excess treatment is eliminated from the body.
Similar to the results seen with SAMe, the group that had been
administered NAC 1 hour after APAP almost completely recovered GSH levels
when compared to the VEH group (FIGURE 54). NAC was able to replenish
GSH lost within 3 hours of administration. When directly comparing the recovery
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GSH results of NAC + APAP vs. SAMe + APAP, we did not see any statistically
significant difference. This does however raise some interesting questions about
whether the use of NAC or SAMe should be used during emergency room
situations involving APAP overdose cases. While both were able to produce a
recovery of GSH levels, NAC was not able to prevent rises in liver weights,
SAMe produced better recovery of plasma ALT values when given post-APAP
and histology favors SAMe as a better antidote in prevention of centrilobular
damage caused by high amounts of APAP. All of the GSH experiments thus far
suggest that this depletion of the compound may not be the major mediator of
APAP-induced liver toxicity.
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Group
VEH
APAP
NAC
NAC + APAP

APAP
No
Yes
No
Yes

NAC
No
No
Yes
Yes

TABLE 28. NAC and APAP treatment regimens.
All injections were given i.p. APAP and VEH were administered 0900 h. NAC
was administered at 1000 h at a dose of 204 mg/kg.

Group

NAC dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g) Liver weight
(g/10g body wt.)

VEH
APAP
NAC
NAC + APAP

0
0
204
204

4
4
4
4

18.0 ± 0.0
17.6 ± 0.4
17.6 ± 0.4
18.0 ± 0.6

a

0.47 ± 0.01
b
0.54 ± 0.01
a
0.45 ± 0.01
b
0.51 ± 0.01

TABLE 29. Body and liver weight following APAP administration.
APAP was administered as 250 mg/kg (15 ml/kg), i.p. 1 hour prior to NAC (204
mg/kg (5 ml/kg), i.p.).

Statistical differences (p < 0.05) are denoted by

superscripts.
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Group

NAC dose
(mg/kg)

Time
post-APAP
treatment (h)

VEH
APAP
NAC
NAC + APAP

0
0
204
204

4
4
4
4

ALT (U/l)

74 ± 26a
12158 ± 1570b
47 ± 10a
801 ± 295c

TABLE 30. Plasma ALT levels following APAP administration.
Groups represent vehicle (VEH); acetaminophen (APAP) injected i.p. 250 mg/kg;
N-acetylcysteine (NAC) i.p. injected 204 mg/kg; NAC and acetaminophen (NAC +
APAP) at doses listed for individual agents. Unlike letters (a, b) indicate groups
are different (p < 0.05) from each other using a one way ANOVA and Tukey’s
post hoc test. Values represent mean ± S.E.M. with n = 4-5 per group.

142

A

Centrilobular
Regions

B

C
143

Centrilobular
Region

D
FIGURE 53. Histological examination 4 hours after APAP injection.
Hepatic tissues were prepared and stained with H&E. Representative slides of
(A)vehicle (VEH); (B) NAC (204 mg/kg) treated; (C) 4 hours post-acetaminophen
(APAP) injection and (D) mice treated with NAC 1 hour after APAP. Normal
morphology was noted in the VEH and NAC animals. Moderate damage was
noted in the APAP group as shown by the arrows in slide C. There was only
limited protection shown in animals dosed with NAC 1 hour post-APAP.
Magnification is 200×.
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FIGURE 54. NAC antidote studies: Total hepatic glutathione levels 4 hours
post-APAP injection in C57Bl/6 mice.
Animals were randomly divided into vehicle (VEH), acetaminophen treated
(APAP), NAC 204 mg/kg treated (NAC) and NAC + APAP treated (NAC +
APAP). Values represent mean ± S.E.M., n = 4–5 mice per group. Total hepatic
GSH levels were measured 4 hours after injection (i.p.) of 250 mg/kg APAP. An
asterisk (*) marks statistically significant difference (p < 0.05) from the rest of the
treatment groups.

145

4.4 Mitochondrial Isolation: Treatments Post-APAP
Effect of 250 mg/kg APAP 1 hour prior to 500 mg/kg SAMe dose
Glutathione can be found in the smooth endoplasmic reticulum, the
cytosol and the mitochondria of the cell. Only about 10-15% of the cell’s GSH is
located in the mitochondria (Fernandez-Checa and Kaplowitz, 2005; FernandezCheca et al., 2002).

More importantly, GSH cannot be synthesized in the

mitochondria. All of the cell’s mitochondrial GSH is brought in by carriers. It has
been found that the cytosolic GSH is the first line of defense against toxic
metabolites such as NAPQI, but under severe circumstances APAP is known to
deplete mitochondrial GSH levels (Reid et al., 2005; Masubuchi et al., 2005; Kon
et al., 2004; Fernandez-Checa et al., 1998). The effect of SAMe on mitochondrial
GSH is not known. These studies examined the dose- and time- dependent
effects of SAMe and APAP on mitochondrial GSH levels.

The glutathione

reductase and glutathione peroxidase studies helped to identify the effects of
SAMe and APAP on the enzymes critical in the balance of oxidized and reduced
GSH. Information is not available in the literature regarding the effects of SAMe
and APAP on these enzymes. Consequently, these studies provide new
information that may be of importance regarding the mechanism for SAMe
attenuation of APAP hepatic toxicity.
Body weight and liver weights for all treated animals are shown in Table
31. Liver weight was increased relative to VEH 4 hours after APAP treatment (p <
0.05). Liver weight was similar between SAMe + APAP, VEH and SAMe groups.
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APAP hepatic toxicity was confirmed by increased liver weight. APAP
increased liver weight when directly compared to the VEH group (TABLE 31),
and SAMe treatment doses were able to prevent the increase in liver weight
attributed to APAP, just as before.
Mitochondria isolation was confirmed by measuring LDH activity. LDH
levels were higher in the supernatant relative to mitochondria (FIGURE 55).
Mitochondria LDH reflects total amount as mitochondria were suspended in 1 ml
of buffer (refer to methods section regarding mitochondrial isolation).
Mitochondrial GSH levels were severely depleted 4 hours post-APAP
injection (FIGURE 56). SAMe, when given 1 hour after APAP was not able to
prevent this decrease in GSH in the mitochondria or the supernatant. This could
possibly be due to inadequate time for GSH to be carried into the mitochondria.
SAMe GSH levels were not statistically different from the VEH in the
mitochondria or supernatant. Further investigation regarding mitochondrial GSH
will need to be done at later time frames to fully illustrate the protective effects (if
any) of SAMe on mitochondrial GSH.
Nitrotyrosine levels were investigated using Western blotting.

Initial

results suggest that SAMe reduces the amounts of nitrotyrosine-adducted
proteins. This, to our knowledge, is the first data suggesting that SAMe might in
fact reduce APAP-induced nitrosylated proteins in the mitochondria (FIGURE
57).
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Group

SAMe dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g) Liver weight
(g/10g body wt.)

VEH
APAP
SAMe
SAMe + APAP

0
0
500
500

4
4
4
4

26.8 ± 0.5
24.8 ± 0.4
24.8 ± 0.8
26.8 ± 0.5

a

0.40 ± 0.01
b
0.51 ± 0.02
a
0.40 ± 0.02
a
0.42 ± 0.01

TABLE 31. Body and liver weight following APAP administration.
APAP was administered as 250 mg/kg (15 ml/kg), i.p. 1 hour prior to SAMe (500
mg/kg (5 ml/kg), i.p.).

Statistical differences (p < 0.05) are denoted by

superscripts.

148

60
VEH
SAMe
APAP
SAMe+APAP

50

LDH (U/l)

40

30

20

10

0

Supernatant

Mitochondria
4 HR

FIGURE 55. LDH activity 4 hours post-APAP treatment.
Mitochondrial and non-mitochondrial LDH activity was measured 4 hours postAPAP injection. Values are expressed as U/l. Groups indicate vehicle (VEH),
SAMe treated (SAMe), acetaminophen treated (APAP) and mice treated with
SAMe 1 hour after APAP (SAMe + APAP). SAMe was administered as 500
mg/kg, i.p. APAP was injected i.p. at a dose of 250 mg/kg (15 ml/kg). Values
represent mean ± SEM with n=4-5 animals/group. Mitochondrial values were
different from respective supernatant (nonmitochondrial) samples.
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FIGURE 56. Total glutathione levels post-APAP treatment in supernatant
and mitochondria.
Non-mitochondrial GSH levels were measured 4 hours after APAP injection.
Values are expressed as µmol/g tissue. Groups are denoted as: vehicle (VEH),
SAMe treated (SAMe), acetaminophen treated (APAP) and mice treated with
SAMe and APAP (SAMe + APAP). Values represent mean ± SEM with n = 4-5
animals/group. Groups with dissimilar superscripts were statistically different
(p<0.05) from each other.
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FIGURE 57.

A nitrotyrosine Western blot of samples 4 hours post-APAP

injection.
Lanes are denoted as: Lane 1 vehicle, Lane 2 SAMe, Lane 3 APAP, Lane 4 SAMe
+ APAP (S + A). SAMe was administered at 500 mg/kg. APAP was injected i.p. at a
dose of 300 mg/kg (15 ml/kg). VEH animals were injected i.p. with water (15 ml/kg).
Highlighted regions represent areas of protection vs. damage.
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Effect of 250 mg/kg APAP 1 hour prior to 204 mg/kg NAC dose
A direct comparison between the two treatments were established to study
the effects on mitochondrial GSH involving NAC or SAMe. To our knowledge,
this type of study had not yet been conducted. This experiment allowed us to
investigate both the ability of SAMe as well as NAC to not only synthesize GSH,
but to also get it into the mitochondria (or protect the mitochondria from GSH
depletion).
Body weight and liver weights for all treated animals are shown in Table
32. Liver weight was increased relative to VEH 4 h after APAP treatment (p <
0.05). Liver weight was similar between NAC + APAP, VEH and NAC groups.
APAP hepatic toxicity was confirmed by increased liver weight. APAP
increased liver weight when directly compared to the VEH group (TABLE 32),
and NAC treatment doses were able to prevent the increase in liver weight
attributed to APAP.
Mitochondria isolation was confirmed by measuring LDH, similar to the
SAMe studies. LDH levels, as expected, were higher in the supernatant relative
to mitochondria (Figures 58).

Mitochondria LDH reflects total amount as

mitochondria were suspended in 1 ml.
Mitochondrial GSH levels were severely depleted 4 hours post-APAP
injection. NAC, similar to SAMe, when given 1 hour after APAP was not able to
prevent this decrease in GSH in the mitochondria or the supernatant (FIGURE
59). This could possibly be due to inadequate time for GSH to be carried into the
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mitochondria. NAC GSH levels were not statistically different from the VEH in
the mitochondria or supernatant. Further investigation regarding mitochondrial
GSH will need to be done.
Nitrotyrosine levels were measured using western blotting. Initial results
suggest that, unlike SAMe, there is little to no reduction in the amount of
nitrotyrosine-adducted proteins.

NAC had no effect in producing nitrosylated

proteins (FIGURE 60) when compared to VEH, but it also didn’t prevent APAPinduced effects on the production of these adducted proteins.
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Group

NAC dose
(mg/kg)

Time post-APAP
treatment (h)

Body weight (g) Liver weight
(g/10g body wt.)

VEH
APAP
NAC
NAC + APAP

0
0
204
204

4
4
4
4

25.6 ± 0.4
26.4 ± 0.7
25.6 ± 0.4
27.0 ± 0.9

a

0.37 ± 0.01
b
0.45 ± 0.02
a
0.37 ± 0.02
a
0.37 ± 0.01

TABLE 32. Body and liver weight following APAP administration.
APAP was administered as 250 mg/kg (15 ml/kg), i.p. 1 hour prior to NAC (204
mg/kg (5 ml/kg), i.p.).

Statistical differences (p < 0.05) are denoted by

superscripts.
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FIGURE 58. LDH activity 4 hours post-APAP treatment.
Mitochondrial and non-mitochondrial LDH activity was measured 4 hours postAPAP injection. Values are expressed as U/l. Groups indicate vehicle (VEH),
NAC treated (NAC), acetaminophen treated (APAP) and mice treated with NAC 1
hour after APAP (NAC + APAP). NAC was administered as 204 mg/kg, i.p..
APAP was injected i.p. at a dose of 250 mg/kg (15 ml/kg). Values represent
mean ± SEM with n = 4-5 animals/group. Mitochondrial values were different
from respective supernatant (nonmitochondrial) samples. An asterisk (*) denotes
statistical difference (p < 0.05) within group.
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FIGURE 59. Total glutathione levels post-APAP treatment in supernatant
and mitochondria.
Non-mitochondrial GSH levels were measured 4 hours after APAP injection and
3 hours post NAC injection. Values are expressed as µmol/g tissue. Groups are
denoted as: vehicle (VEH), NAC treated (NAC), acetaminophen treated (APAP)
and mice treated with NAC and APAP (NAC + APAP). Values represent mean ±
SEM with n = 4-5 animals/group. Groups with dissimilar superscripts were
statistically different (p<0.05) from each other.
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FIGURE 60. Western Blot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1 vehicle, Lane 2 NAC, Lane 3 APAP, Lane 4 NAC
+ APAP (N + A). NAC was administered as 204 mg/kg. APAP was injected i.p.
at a dose of 300 mg/kg (15 ml/kg). VEH animals were injected i.p. with water (15
ml/kg).
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4.5 HPLC Analysis
Investigation into the production and quantification of particular APAP
metabolites was undertaken to better understand the mechanisms of action for
both SAMe and APAP. Research techniques for quantification of both drugs
have been developed (Aboul-Enein and Abu-Zaid, 2001; Dietze et al., 1997;
Esteban et al., 1992; Esteban et al., 1993; Wang, 2001; Fischer et al., 1981;
Hamedani et al., 1993; Jensen et al., 2004; Miners et al., 1984; Vertzoni et al.,
2003; Wang and Cederbaum, 2006; Moldéus, 1978), but none of the studies
examined the effects of SAMe on APAP metabolites. Of the procedures listed
above, we chose to use the methods of Vertzoni et al. (2003) and Moldéus
(1978).

These two methods gave detailed instruction on the procedures of

isolating the metabolites along with flow rates and column specificities, plus had
a fairly short retention time for each sample allowing for an efficient overall
procedure (roughly 20 minutes/sample).
We quantified APAP and two of its metabolites, sulfated- and
glucuronidated-APAP Figures 61-64). Data represents APAP and sulfated-APAP
concentration differences between animals treated with a dose of 300 mg/kg
APAP i.p. (APAP) or animals injected (i.p.) with 500 mg/kg SAMe just prior to 300
mg/kg APAP (SAMe + APAP). HPLC analysis was done on plasma and hepatic
tissue collected 1, 2 or 4 hours post-APAP or VEH injection (FIGURES 61 - 64).
The glucuronidated-APAP showed no statistical difference between each of the
two treatment groups (data not shown).
158

In the plasma, animals dosed with APAP had lower concentrations of
APAP than animals given SAMe just prior to APAP. At both 1 and 2 hours postAPAP, the SAMe + APAP group showed statistically significant (p < 0.05) higher
amounts of APAP (FIGURE 61). At 4 hours post-APAP there was still a general
trend for higher concentrations of APAP, but it was not statistically significant.
Also in the plasma, levels of the sulfated-APAP were higher in the SAMe + APAP
group than when directly compared to the APAP dosed animals.

For the

sulfated-APAP, statistically significant differences between the APAP and SAMe
+ APAP groups were seen at 2 and 4 hours post-APAP injection (FIGURE 62).
In the liver, no significant difference was seen in APAP concentrations
between the groups at 1, 2 or 4 hours post-injection (FIGURE 63). Both groups
showed the same general trend of a steady decrease in the amount of APAP in
the liver as time passed. However, there were statistically significant differences
seen in the amount of sulfated-APAP concentrations between the two groups 1
hour post-APAP. In animals dosed with SAMe just prior to APAP, there was a
higher amount of sulfated-APAP present in the liver (FIGURE 64). The other two
time studies (2 and 4 hours post-APAP), did not show any significant differences
between the two groups.
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FIGURE 61. HPLC data of APAP concentration in plasma.
Plasma levels were measured 1, 2 and 4 hours after APAP injection. Values are
expressed as µg/ml. Groups are denoted as: acetaminophen treated (APAP) and
mice treated with SAMe and APAP (SAMe + APAP). Values represent mean ±
SEM with n = 4-5 animals/group. Groups with an asterisk (*) were statistically
different (p < 0.05) from the other group at the same time frame.
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FIGURE 62. HPLC data of APAP-SO4 concentration in plasma.
Plasma levels were measured 1, 2 and 4 hours after APAP injection. Values are
expressed as µg/ml. Groups are denoted as: acetaminophen treated (APAP) and
mice treated with SAMe and APAP (SAMe + APAP). Values represent mean ±
SEM with n = 4-5 animals/group. Groups with an asterisk (*) were statistically
different (p < 0.05) from the other group at the same time frame.
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FIGURE 63. HPLC data of APAP concentration in liver.
Levels were measured 1, 2 and 4 hours after APAP injection. Values are
expressed as µg/g tissue. Groups are denoted as: acetaminophen treated
(APAP) and mice treated with SAMe and APAP (SAMe + APAP). Values
represent mean ± SEM with n = 4-5 animals/group.
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FIGURE 64. HPLC data of APAP-SO4 concentration in liver.
Levels were measured 1, 2 and 4 hours after APAP injection. Values are
expressed as µg/ml. Groups are denoted as: acetaminophen treated (APAP) and
mice treated with SAMe and APAP (SAMe + APAP). Values represent mean ±
SEM with n = 4-5 animals/group. Groups with an asterisk (*) were statistically
different (p < 0.05) from the other group at the same time frame.
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4.6 Proteomics
As described previously, liver samples were prepared and shipped on ice
to Dr. Serrine Lau at the University of Arizona. Dr. Lau confirmed our findings
regarding protein carbonyls using an OxyBlot. The OxyBlot, similar to the results
we received in our laboratory, showed a strong increase in carbonyl groups in the
APAP group as compared to the control. The SAMe group was similar to the
control group and was significantly protected from APAP-induced protein
oxidative modifications. Figure 65 shows the protein bands that were excised
from the OxyBlot, trypsin digested, and analyzed on the LCQ ion-trap (Deca)
LC/MS-MS at the University of Arizona. After trypsin digestion and LC/MS-MS
analysis the data was analyzed with Turbo SEQUEST. Table 33 shows proteins
that were identified in each band.

The raw data was also analyzed by

X!Tandem, a valid protein hit was required to be present in both the SEQUEST
and X!Tandem data. A protein sequence database was created from Table 33
and used to search the raw data for 4-HNE adducts using PMOD. There were
several 4-HNE adducts identified, two of which were confirmed using X!Tandem.
The two peptides with promising PMOD scores and confirmation using
X!Tandem were then manually validated using SpecPlot (Figure 66 and 67).
Both peptides showed excellent coverage of b and y ions and were both found
with X!Tandem and PMOD, adding to the confidence of an accurate adducted
peptide identification. Both proteins are compartmentalized in the mitochondria
and recent literature suggests mitochondrial proteins are targets of APAP
induced hepatocellular protein adduction, further validating our findings
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(Masubuchi et al., 2005). These data, run in collaboration with Dr. Lau, support
our hypothesis of SAMe working via mechanisms other than GSH production. As
reported here, SAMe is also able to prevent protein modifications induced by
APAP overdose.
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FIGURE 65. OxyBlot ran at the University of Arizona.
A) Gel electrophoresis of 40 µg for all groups. The first lane was loaded with a
molecular weight marker (kDa). B) Shows the protein bands excised for LC/MSMS analysis from the same gel as in figure 67A.
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Band

Protein

Accension
number

Molecular
weight

Num. of
Peptides

% Coverage

1

GRP78 (glucose regulated protein precursor)

gi|2506545|

72,422

3

7.6

2

Aldehyde Dehydrogenase

gi|24418394|

98,709

14

18.2

Sarcosine Dehydrogenase

gi|52000836|

101,682

8

10.1

Transferrin

gi|20330802|

76,724

14

27.0

Heat Shock 70 Protein

gi|1661134|

70,837

13

19.3

Tubulin alpha 2

gi|539933|

50,036

3

3.8

Carbamoyl-phosphate synthetase isoform 1

gi|82879179|

164,618

14

35.0

5

Gent1 protein

gi|24657508|

49,832

4

3.3

6

Dodecenoyl-Coenzyme A delta isomerase

gi|12836323|

32,250

4

20.4

3

4

Carbonic anhydrous III

gi|3198286|

29,366

3

11.5

7

ADP-Ribosylation factor 2

gi|14714692|

20,710

3

22.1

8

Gamma-Actin

gi|80956|

41793

7

21.7

TABLE 33. Altered proteins post-APAP injection in male C57Bl/6 mice.
Shows proteins identified in each band excised. Each protein was required to
have a minimum of 3 peptides identified from SEQUEST with reasonable spectra
in order to be accepted. Also, the raw data was analyzed using X!Tandem, the
above table represents proteins fitting the initial criteria as well as being
represented in both SEQUEST and X!Tandem.
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Carbamoyl-Phosphatase Synthetase 1, isoform 1 (gi|82879179|)
b

.

LR(154)DADPILRC(57)EMASTGEVAC(57)FGEGIHTAFLK y
y30+3 +H2O

y13+1

b25+2
y12+1

y10+1

y8+1
y11+1
b11+2
-H2O
b6+2
-H2O

y5+1

y14+1
y6+1
y7+1

y16+1

y26+2
b14+2

y12+1
-NH3

1035.1

y17+1

y15+1

FIGURE 66. Manual validation of an adducted peptide from CarbamoylPhosphate Synthetase 1, isoform 1.
This protein is localized in the mitochondria. The second amino acid in this
peptide (R) is adducted with a mass of 154 which corresponds with an addition of
4-HNE.

The addition of 57 to the two cysteines is iodoacetamide and is a

product of the reduction and alkylation step prior to the trypsin digestion. The
dots above or below the amino acids of the peptide above represents ions
identified within the spectrum.
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Sarcosine Dehydrogenase, Mitochondrial Precursor (Swiss-Prot Q64380)
y7+1

.
. .. . ........ .

b
LM(16)SLGK(154)AYGIESHVLSPAETK y
y17+2

y6+1
y5+1

y10+1
y13+2

y9+1
y8+1
y11+1
y19+2
1070.4

b9+2
y3+1

FIGURE 67.

y5+1
-H2O

y15+2
-H2O

y11+1
-H2O

792

y16
+2

Manual validation of an adducted peptide from Sarcosine

Dehydrogenase, mitochondrial precursor.
This protein is localized in the mitochondria. The sixth amino acid in this peptide
(K) is adducted with a mass of 154 which corresponds with an addition of 4-HNE.
The addition of 16 to the second amino acid (M) implies an oxidation of the sulfur
on the side chain of the methionine. The dots above or below the amino acids of
the peptide above represents ions identified within the spectrum.
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CHAPTER V
Summary and Conclusion
5.1 General Toxicity
Physiological Changes Upon APAP Treatment
It is known that acetaminophen (APAP) is harmful if taken in excessive
doses. Studies have been conducted involving doses of APAP up to 1000 mg/kg
(Bray et al., 1992).

Several treatment modalities have been investigated as

antidotes for APAP toxicity and include N-acetylcysteine (NAC), vitamin E,
melatonin (Sener et al., 2003) and S-Adenosyl-L-methionine (SAMe) (Valentovic
et al., 2004; Stramentinoli et al., 1979). However in past studies, the end result
was typically animal survival (Stramentinoli et al., 1979; Bray et al., 1992). We
wanted to look further into the mechanistic properties of not only APAP, but also
how SAMe (and NAC) attenuates APAP-induced hepatotoxicity.
Previous studies have shown APAP to be toxic to the liver; however the
mechanism of APAP is not well characterized. The goal of this study was to help
characterize APAP toxicity in an in vivo model and develop a hypothesis into
potential treatments, such as S-Adenosyl-L-methionine (SAMe), to attenuate
APAP-induced hepatic toxicity. In order to make any substantial conclusions
about the mechanism of APAP or by which the treatment worked, APAP toxicity
was first characterized in our mouse model.
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The dose of APAP used in this study ranged from 250 to 500 mg/kg.
These doses were chosen based on the following: (1) the concentration of 250
mg/kg was the lowest dose used, but was determined to still yield toxic effects in
the liver; (2) the 500 mg/kg SAMe dose was chosen based on past literature
(Bray et al., 1992; Stramentinoli et al., 1979) investigating APAP-induced liver
injury.
APAP was directly toxic to the mouse liver via a dose- and timedependent mechanism. APAP produced a loss of cell viability and increased
oxidative stress as illustrated by the histology slides, increased plasma ALT
values, and depleted glutathione (GSH) levels. This effect was seen at all doses
of APAP. These results and initial characterization of SAMe protection of APAP
toxicity have been published by our laboratory (Valentovic et al., 2004). GSH
levels were depleted up to 90% 4 hours post-injection in APAP dosed animals.
These GSH values are comparable to what has been seen in prior studies
(Arnaiz et al., 1995; Liu et al., 1999). APAP also induced toxicity in a timedependent manner.

Stronger indications of damage, i.e. higher plasma ALT

values, lower GSH levels and histological alterations, were seen in livers excised
with longer post-APAP injection times. However, damage was seen as early as
1 hour post-APAP injection. While the time-dependent toxicity of APAP has been
reported, this is the first study to document hepatic damage within 60 minutes of
APAP administration. These data demonstrate the rapidity with which APAP
causes damage to the liver. This information also reiterates the importance of
knowing the exact mechanism of APAP-induced hepatotoxicity and ways to
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improve on treatments given to patients in desperate need of an antidote. These
studies investigated a potential new remedy for APAP-overdose cases.

By

directly comparing the therapeutic effects to animals dosed with only APAP and
by showing the benefits of SAMe vs. NAC, we have provided new information
regarding the treatment of APAP overdose cases.

5.2 Treatments Just Prior to APAP
The role of SAMe in attenuating APAP-induced hepatic toxicity has been
postulated to include production of GSH.

To date, there have been many

publications involving different dosing regimens of SAMe just prior to different
doses of APAP. However, in all of these previous studies, the primary parameter
measured was survival rate. Previous studies had compared survival rates 21
and 48 hours after APAP treatment and have used mortality as an endpoint.
SAMe pretreatment (Stramentinoli et al., 1979; Bray et al., 1992) in these studies
was assessed only by hepatic function and morphology in surviving animals 21
and 48 hours after APAP treatment. Evaluation at this late stage does not
provide an accurate measurement of the effects of SAMe on APAP-mediated
GSH depletion, which is thought to be critical to the development of toxicity.
Consequently, our current understanding of the effects of SAMe on APAP toxicity
at the onset of hepatic necrosis is not well known. In addition, these earlier
studies evaluated only the effect of SAMe on APAP toxicity and did not assess
the effect of SAMe alone on the liver (Bray et al., 1992).
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We wanted to further investigate the abilities of SAMe as a
hepatoprotectant for APAP hepatotoxicity. The first experiments were designed
to establish the protective threshold SAMe could provide against APAP-induced
liver damage. Pre-treatment experiments using SAMe (and NAC) were utilized
to help establish the baseline of protection against APAP-induced hepatotoxicity
and provide information regarding the time-and dose-dependent attenuation of
liver damage caused by APAP. The effect of different doses and time after
administration of SAMe on APAP-induced hepatotoxicity had not been reported.
Furthermore, studies have not been published examining the time course for
SAMe’s hepatoprotective effects for APAP. During our initial studies involving
SAMe in our laboratory, we used 1000 mg/kg of SAMe just prior to 500 mg/kg
APAP. We found that this large dose did attenuate the APAP-induced damage,
but as we further explored the properties of SAMe, we found that half of our initial
dose worked just as well. We also found that doses as small as 250 mg/kg
APAP can still elicit severe damage in the mouse liver thus decreasing the
possibility of drug-induced mortality of the mice.
Data collected regarding the abilities of SAMe to attenuate damage
caused by APAP overdose when given just prior to APAP strengthened the
theory that SAMe does produce GSH. However, since the degree of restoration
of GSH levels was small relative to reversal of hepatotoxicity, the experiments
raised the question of whether SAMe might operate through pathways not
involving GSH production. These data show not only increased GSH production
in animals dosed with SAMe just prior to APAP vs. animals given just APAP, but
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the treatment also lowered plasma ALT values, lessened histological changes
decreased protein carbonyl and 4HNE-adducted protein levels as well as
prevented rises in liver weights.

Effect of 1000 mg/kg or 500 mg/kg SAMe just prior to 500 mg/kg APAP dose
Considerable variability exists within the literature for the reported dose of
SAMe that will reduce APAP toxicity.. Initial studies (Stramentinoli et al., 1979)
and many thereafter (Song et al., 2004) used doses of SAMe up to 1000 mg/kg.
For our studies we used an initial dose of 1000 mg/kg.
We found that SAMe protected mice from APAP hepatic toxicity at both
1000 and 500 mg/kg dosings. Mild hepatic degeneration begins in the
centrilobular region as early as 1 hour after APAP injection and at 4 hours, livers
have necrotic and degenerative changes in the midzonal and periportal regions.
This finding was also reported by Placke and colleagues (1987). Centrilobular
necrosis is more severe at 6 and 8 hours after APAP injection (Placke et al.,
1987; Esteban et al., 1993).

SAMe pretreatment prior to APAP injection

protected against hepatotoxicity as indicated by the absence of centrilobular
necrosis 4 hours after APAP treatment. Stramentinoli et al. (1979) reported that
centrilobular necrosis was very limited 24 hours after APAP injection in SAMe
pretreated mice. The late assessment of histology, however, was done only in
surviving animals as APAP had a 43% incidence of mortality and SAMe
pretreatment reduced mortality to 8%.
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APAP

hepatotoxicity

requires

cytochrome

P450

mediated

biotransformation of acetaminophen to the toxic metabolite, N-acetyl-pbenzoquinone imine (NAPQI) (Mitchell et al., 1973b). Detoxification of APAP’s
toxic metabolite requires adequate levels of GSH (Walker et al., 1982; Potter and
Hinson, 1986). Hepatic damage ensues when GSH levels become depleted. It is
well documented that GSH levels rapidly fall in mice treated with APAP and are
decreased below control values within 1 hour of APAP administration (Hinson et
al., 1981). GSH levels are depressed in mice by 78% within 2 hours by an oral
dose of 600 mg/kg APAP (Placke et al., 1987). Bray et al. (1992) noted plasma
GSH levels were decreased by APAP 2 hours after injection and in surviving
animals returned to near normal levels within 9 hours. Plasma GSH levels were
less extensively diminished in APAP animals pretreated with SAMe at 2 hours
after APAP but values were not given for any other time period. In our studies,
1000 or 500 mg/kg SAMe administration just prior to 500 mg/kg APAP injection
provided partial protection from the depletion in hepatic GSH when measured 2
and 4 hours after APAP injection. A lower dose (500 mg/kg) of SAMe did not
provide the same level of protection of hepatic GSH but was able to maintain
higher GSH levels than APAP treated groups. In addition, the lower dose of
SAMe (500 mg/kg) was able to provide an increase in baseline hepatic GSH. The
higher dose of SAMe (1000 mg/kg) did not increase baseline GSH levels.
Although it would be expected that baseline GSH levels should be increased by
agents that are precursors for GSH, the response to some agents is variable in
the liver. Previous studies with NAC, the antidote for APAP toxicity, showed that
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NAC does not increase baseline GSH levels when administered at a dose
sufficient to lower hepatic toxicity in mice (Sener et al., 2003) and rats (Raza et
al., 2003). Sener and associates reported a decrease in hepatic APAP induced
toxicity but not a change in baseline hepatic GSH levels with NAC treatments. A
similar effect was noted when NAC was administered to Wistar rats (Raza et al.,
2003). This may also be part of the mechanism of GSH production: if GSH is not
needed, then it is simply not produced.
SAMe pretreatment prior to APAP injection further prevented a rise in
hepatic lipid peroxidation 2 and 4 hours after APAP injection. In our studies,
APAP alone markedly increased lipid peroxidation. The rise in lipid peroxidation
by APAP was in agreement with reports by other laboratories that noted APAP
increased lipid peroxidation in mice (Ozdemirler et al., 1994). The mechanism
for SAMe protection against the hepatotoxic effect of APAP is not completely
known,

but

quite

possibly

involves

GSH.

Studies

have

shown

that

supplementation with SAMe can reverse hepatic damage in humans associated
with liver diseases including alcoholic liver and intrahepatic cholestasis (Frezza
et al., 1990; Lieber, 1997, 2002).

SAMe pretreatment of baboons or mice

reduced alcohol induced liver damage by preventing GSH depletion (Lieber et
al., 1990; Song et al., 2003). SAMe is a substrate for transmethylation reactions
to form SAH and homocysteine (Finkelstein, 1990). The trans-sulfuration
pathway then converts homocysteine to cysteine, a substrate for GSH synthesis
(Lu, 2000). It is plausible that the protection by SAMe against APAP
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hepatotoxicity is mediated by a similar mechanism and therefore can better
explain the protection seen with this experiment.

Effect of 500 mg/kg SAMe just prior to 400 mg/kg APAP dose
After the initial results with 500 and 1000 mg/kg of SAMe with the fed
animals, we found that 500 mg/kg protected just as well, if not better than, 1000
mg/kg SAMe. For the remaining experiments reported in this thesis we used 500
mg/kg SAMe. We also decided to fast the animals overnight (1700-0900 h). We
found that after 7-10 days in the animal facilities, the mice are known to start
establishing dominance with their cage-mates. This can affect eating habits of
the other mice if not rectified. To eliminate the possibility of all the animals not
eating the same amounts the night before, food was removed. This added extra
assurance that we were getting the most consistent results possible and by
fasting the animals we were able to better establish the true effects of SAMe on
the liver.

By eliminating confounding factors, such as food, we could better

establish the abilities of SAMe to produce GSH and attenuate APAP-induced
hepatotoxicity.
We also lowered the amount of APAP dose from 500 mg/kg to 400 mg/kg.
Since we had already established that 500 mg/kg APAP in fed animals induced
severe hepatic toxicity, we postulated that less APAP would be needed in fasted
animals. It was decided that we would lower the dose to 400 mg/kg APAP and
measure the new toxicity levels with GSH, lipid peroxidation, plasma ALT and
protein assays. We also had Dr. Betts Carpenter examine morphology by light
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microscopy to check for centrilobular necrosis and verify that APAP was toxic in
the animals at this level.
The APAP-induced hepatic toxicity was confirmed with our measurable
assays and we now had a new treatment dose to examine the effects of both
APAP and SAMe on attenuating APAP-induced toxic effects. This particular data
set explored very early effects of toxicity seen 1 hour post-APAP injection. We
were not only able to document the therapeutic effects of SAMe attenuating
APAP-induced liver injury, but we were able to display some of the early
showings of toxicity and how it evolves into more dramatic injury 4 hours postAPAP overdose.
With 400 mg/kg APAP, SAMe was able to prevent hepatotoxicity as
indicated by all parameters. Stramentinoli et al. (1979) confirmed the beneficial
effects of SAMe when given just prior to APAP by percent of animals that
survived.

In our study, toxicity started to occur within 1 hour post-APAP

treatment and SAMe reversed certain indicators of hepatotoxicity.

The only

protection that was not seen was a statistically significant rise in GSH levels.
This was most likely due to the short time frame post-SAMe treatment. At 4
hours post-APAP, GSH levels began to increase in animals given SAMe just
prior to APAP treatment compared to the animals not pre-treated with SAMe.
Earlier time frames did not give the animal adequate time to replace GSH that
was lost due to oxidation by NAPQI.
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Effect of 500 mg/kg SAMe just prior to 300 mg/kg APAP dose
In order to establish a threshold dose for APAP-induced hepatotoxicity we
lowered the dose to 300 mg/kg APAP. We had continually received consistent
results regarding the initial treatments, but we also wanted to discover a
threshold for toxicity regarding APAP in mice. As expected, larger amounts of
APAP can sometimes affect the mice differently. Some are able to handle larger
doses, such as 1000 mg/kg APAP, better than others. The end results when
using larger amounts of APAP usually contain many inconsistencies when trying
to measure different toxicological parameters and establish statistically significant
differences.
In our laboratory, we confirmed that a 1 hour post-APAP 300 mg/kg
injection resulted in toxicity within the liver as defined by: increased liver weights,
plasma ALT values increased and histological damage was seen around the
centrilobular region.

We also found that this toxicity increased in a time-

dependent manner. As previously reported (Valentovic et al., 2004), GSH levels
are markedly decreased 1 hour after APAP injection and continue to be
significantly lower than the VEH group 4 hours post-APAP injection.

These

decreases were also seen with 300 mg/kg APAP dosing 1, 2 and 4 hours postinjection. What was interesting was the continued increase in GSH stores in
animals dosed with SAMe just prior to APAP as compared to those dosed only
with APAP. We have shown the continuous increase in GSH stores from 1 hour
post-APAP injection to 4 hours post-injection. These data confirmed our belief of

179

protective effects of SAMe, including antioxidant behavior, are based on a timedependent manner.

Effect of 500 mg/kg SAMe just prior to 250 mg/kg APAP dose
In our last set of experiments we used 250 mg/kg APAP. This is the
lowest amount of APAP-induced toxicity data established. Previous studies did
not, for the most part, identify APAP overdose-induced effects on GSH levels,
liver weights, histological changes or other parameters.

It had already been

established in our laboratory that 500, 400 and 300 mg/kg APAP were toxic. It
had also been established that SAMe can attenuate the levels of extreme toxicity
of APAP at a dose of 500 mg/kg within 1 hour of induced toxicity. These data
furthered our understanding of both the effects of lower amounts of APAP in the
body as well as the benefits of SAMe when given just prior to the APAP dose.
Abilities of SAMe, when given just prior to 250 mg/kg APAP, included, but are not
limited to, lowering plasma ALT levels, decreasing oxidative stress as measured
by 4-hydroxy-2-nonenal (4HNE) adducted proteins and protein carbonyls,
increasing GSH stores and attenuating APAP-induced increases in liver weight.

Effect of 204 mg/kg NAC just prior to 300 mg/kg APAP dose
Abilities of SAMe to attenuate APAP-induced hepatic toxicity needed to be
directly compared to a therapeutic agent that is currently used to treat APAP
overdose cases: N-acetylcysteine (NAC). In the United States, as with other
countries such as the United Kingdom and Australia (James et al., 2003), NAC is
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the drug of choice in treating patients who have voluntarily or involuntarily
overdosed on APAP. The treatment regimen of NAC is quite vigorous (over 17
doses including a loading dose) when treating overdose patients. However, we
wanted to directly compare the effects seen with SAMe vs. the protective effects
of NAC. To do this, NAC was administered at the same concentration as SAMe,
1.25 mmol (204 mg/kg).
Data has been published on the benefits of NAC (Lawson et al., 1999;
James et al., 2003; Prescott, 1981). Therefore, our results seen when NAC was
given to APAP-injected mice were quite surprising.

Liver weights started to

increase only 1 hour post-APAP. At 4 hours post-APAP, animals dosed with only
APAP yielded a statistically significant rise in liver weight. However, unlike the
studies when animals were given SAMe just prior to APAP, whenever NAC was
dosed just prior to APAP, there was not a decrease in liver weight. NAC was
also unable to prevent a rise in plasma ALT values 4 hours post-APAP.

There

was no statistically significant difference between the APAP group and the NAC
+ APAP group. Histology showed moderate damage around the centrilobular
region in groups pretreated with NAC just prior to APAP and decreased GSH
levels were not reversed.

OxyBlot and 4HNE gels also portrayed the same

conclusions: NAC, at the same mmol dose of SAMe, is not able to prevent
damage caused by 300 mg/kg APAP. To summarize, this dose of NAC is not
equivalent to an antidote dose given to patients who have overdosed and SAMe
is more potent that NAC in our model. These observations are the first to truly
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investigate the possibility that SAMe may protect better than today’s APAP
overdose antidote: NAC.

Effect of 500 mg/kg SAMe just prior to 1000 mg/kg DEM
Diethyl maleate (DEM) is a known GSH depleting agent that directly binds
to GSH (Casey et al., 2002). Consequently once DEM is bound to GSH, the
GSH can not provide any type of antioxidant support or protection. However,
new GSH can be produced provided cysteine is available. DEM has no effect on
the enzymes involved in glutathione synthesis and GSH can occur after DEM
treatment (Casey et al., 2002; Hosoya et al., 2002).
This fact is illustrated in our time-dependent studies with DEM. By fasting
the animals prior to DEM treatment, they have no substrate available to make
new GSH and we can, therefore, study the effects of SAMe on the production of
new GSH.

With the effects of DEM in mind, we designed these studies to

investigate the time-dependent properties/abilities of SAMe to produce new GSH.
The treatment dosing and time frames mimic those done by Casey and
colleagues (2002). Animals were treated as before: fasted the night prior to
injection with free access to water, blood drawn and toxicity parameters
measured. Toxicity parameters included liver weights to insure that DEM had no
toxic effects at the treatment dose.
Baseline GSH levels were established in VEH, DEM and SAMe + DEM
treatment groups. GSH levels found in VEH and DEM groups were comparable
to values published by Bray and Rosengren, 2000. As expected, GSH levels
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were not markedly increased in SAMe + DEM groups until 4 hours post-DEM.
Animals that were treated with SAMe + DEM showed no statistically different
changes in GSH values 2 hours post-DEM. At 4 hours post-DEM, it was found
that animals dosed with SAMe just prior to DEM yielded approximately a 50%
increase in GSH levels when directly compared to animals given only DEM. This
supports data found in our earlier studies: SAMe is in fact a time-dependent
treatment that does elicit protective effects, but some of which (such as GSH
production) are not detectable until 4 hours after treatment. It also reiterates the
theory of SAMe’s protective ability to produce new GSH.
This experiment enabled us to answer questions regarding the abilities of
SAMe to produce new GSH.

It also strengthened the SAMe mechanism

published by Lu (1999) regarding GSH production using SAMe. New questions
were also derived from this experiment. These questions include: (1) how do
these GSH levels compare with NAC + DEM when NAC is given at a same mmol
dose and (2) due to the time frame needed to produce a statistically significant
rise in GSH levels, what other protective pathways is SAMe working by to
provide protection earlier on?

Effect of 204 mg/kg NAC just prior to 1000 mg/kg DEM
To directly compare the properties of SAMe in production of GSH, we
once again had to treat the animals with a known producer of GSH: NAC. The
known pathway of NAC in production of GSH as shown in Figure 39, has been
published (Lawson et al., 1999). NAC is a producer of cysteine, the rate-limiting
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compound in the production of GSH.

We wanted to conduct a study that

involved a direct comparison of utilizing the production of cysteine in the timedependent GSH production using NAC vs. SAMe. Through this experiment we
were able to directly compare the capabilities of both SAMe and NAC in the
production of new GSH.
As described above, animals were dosed and toxicity parameters (liver
weights) were checked to insure DEM had no toxic effects besides depleting
GSH levels. Just as before, DEM significantly reduced GSH levels only 2 hours
post-injection and these values remained depleted 4 hours post-DEM injection.
However, unlike what we recorded with SAMe involving DEM, NAC was not as
hepatoprotective and unable to elicit increases in GSH levels 2 and 4 hours postDEM injections.

Values of GSH remain depleted and statistically similar to

animals given only DEM at both time frames.
The ability of SAMe to modulate an increase in GSH at a faster rate than
NAC strengthened our initial data and further provided evidence that SAMe,
when given in a same mmol dose as NAC, is more potent and protects better
than NAC with regards to GSH production. These data also raise the question of
whether GSH production is a significant factor involving the ability of SAMe to
provide protection against APAP-induced hepatotoxicity.

We have shown

abilities of SAMe that included reversing histological alterations around the
centrilobular region of the liver, decreasing ALT values, preventing rises in liver
weights and lowering concentrations of protein carbonyls and 4HNE-adducted
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proteins. This new information now documents the potential of SAMe vs. NAC in
providing support to a stressed liver by providing GSH at a faster rate.

Effect of 250 mg/kg SAMe + 102 mg/kg NAC just prior to 300 mg/kg APAP dose
Our data on the effect of SAMe vs. NAC suggest that the two treatments
may work via different mechanisms.

NAC mechanism has been well

documented (Lauterburg et al., 1983; Marzullo, 2005) and one potential pathway
of SAMe (Lu, 1998) involves a very similar mechanism. Yet, to our knowledge
no known data had been published on a therapeutic cocktail involving both SAMe
and NAC.

Other antioxidant treatments have been studied, some of which

include vitamin E and melatonin (Sener et al., 2003). We had seen promising
protection by SAMe and a potential of NAC on a same mmol basis.
Treatment dosings were chosen based on our earlier studies as previously
described. To draw direct conclusions between each of the treatments, we had
to keep the same mmol concentration of doses. Consequently, the doses of both
SAMe and NAC were cut in half to yield the same final concentration. Beyond
this, animals were treated the same as before and all measurable parameters
were carried out.
The SAMe + NAC combination experiments gave unexpected results.
Despite NAC not yielding any protective effects with our previous studies
involving 204 mg/kg just prior to APAP, we had expected to see some protection.
The combination therapy was unable to prevent APAP-induced liver toxicity and
increased ALT values. GSH levels were depleted at both 1 and 4 hours post185

APAP injection. The combination treatment when given just prior to APAP, was
unable to increase GSH levels when directly compared to the APAP group. In
fact, results seen were very similar to animals dosed with NAC only just prior to
APAP.

The inabilities of SAMe + NAC to attenuate APAP-induced hepatic

toxicity were also seen in the protein carbonyl and 4HNE-adducted protein levels.
In all parameters measured, the only positive result seen was lipid peroxidation
values.

The SAMe + NAC predose was able to attenuate APAP-induced

increases in TBARS. This was the only protection that was recorded for the
SAMe + NAC combination treatment.
We wanted to address the question of whether a combination treatment
would yield similar or even synergistic effects. We expected that if the two drugs
did in fact work via the same mechanism, then we should see similar results with
respect to GSH production, decreases in plasma ALT values, lowered liver
weights, etc. Also, if the two drugs worked via same mechanisms, when given
together there could be a possibility of synergistic behavior.

Ultimately, this

experiment was designed to help better establish the main mechanism of SAMe
utilization during APAP-induced liver damage.

Results from this experiment

helped us answer the question of whether GSH production was the main and/or
only protective pathway of SAMe regarding attenuation of APAP-induced liver
damage. After the completion of this study, our initial beliefs were supported:
SAMe probably is working via other mechanisms besides GSH production. The
lowered mmol concentrations of SAMe (0.625 mmol/kg) and NAC (0.625
mmol/kg) when combined together yielded poor protective results. These data
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illustrate the hypothesis that if the two drugs worked via the same mechanism,
we should have at least seen results comparative of earlier experiments.

Positive Control: High dose of NAC
We have used NAC in our mouse studies at doses much lower than those
used therapeutically in humans. The doses of NAC given in emergency room
situations involving cases of APAP overdose are quite large: 140 mg/kg loading
dose followed by 70 mg/kg doses every 4 hours for a total of at least 17 doses.
The therapeutic effects of NAC have been shown.

However when directly

compared on a mmol basis to SAMe, NAC was unable to provide any statistically
significant protection in our laboratory. To confirm the protective effects of NAC
in our mouse model as well as dismiss any questions of the abilities of NAC in
our laboratory, we chose a dose amount (1200 mg/kg) similar to concentrations
previously reported to attenuate APAP (James et al., 2003).
When we used 1200 mg/kg NAC we found excellent protection in all
measure of toxicological parameters measured. NAC prevented rises in liver
weight, plasma ALT values, prevented histological alterations induced by APAP
and it prevented rises in levels of oxidized proteins as shown by Western blotting.
These results confirmed that a high dose of NAC does in fact prevent APAPinduced hepatic toxicity in our laboratory.
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Effect of 3.84 mg/kg vitamin B6 + 500 mg/kg SAMe just prior to 300 mg/kg APAP
Lu (1998) hypothesized that vitamin B6 plays a vital role in the production
of SAMe into GSH. In fact, Lu states that vitamin B6 is a rate-limiting factor when
it comes to the proposed SAMe mechanism. Therefore, we tested the effect of
vitamin B6 + SAMe on protection from APAP-induced hepatotoxicity. A vitamin
B6 dose comparable to what a human recommended daily dosage was used.
Results showed limited protection with respect to vitamin B6 + SAMe just
prior to APAP. At 1 hour post-APAP injection there was no notable protection
seen in any of the measured assays. GSH levels as well as plasma ALT values
were very similar in the vitamin B6 + SAMe + APAP group when directly
compared to the APAP group 1 hour post-injection.

At 4 hours post-APAP

injection, some protection was seen especially in the GSH levels and lipid
peroxidation values as well as liver weights. While limited response was seen
early on, 4 hours post-APAP injection recorded an increase in GSH levels of over
50% in animals given the pretreatment as compared to those dosed only with
APAP.

Plasma ALT values were also diminished (almost 50%), but the

protection seen with respect to SAMe were not as promising. TBAR production,
as measured by the lipid peroxidation assay, yielded excellent protection 4 hours
post-injection in animals dosed with vitamin B6 + SAMe just prior to APAP.
Protection by vitamin B6 + SAMe yielded the best results of all treatments in the
lipid peroxidation assay.
These data are the results testing the hypothesis first proposed by Lu
(1998) that vitamin B6 may be an important factor in the production of GSH from
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SAMe.

Our results were not sufficient to prove or disprove this hypothesis.

Further studies involving vitamin B6 and SAMe are needed. These studies would
examine the beneficial effects of vitamin B6 when administered after APAP. The
inconclusive data recorded most likely was the result of the SAMe mechanism
itself. If GSH was not immediately needed, excess SAMe and vitamin B6 were
probably eliminated from the body or used elsewhere. No GSH can be produced
if the ratio of SAH:SAMe favors SAH. The mechanism as portrayed by Lu (1998)
is reversed and no GSH is made. Instead, the parent compound of the SAH,
SAMe, remains. Further investigation using this treatment cocktail would need to
be done to strengthen these claims. The investigation should include a postAPAP treatment. Only then could the protective effects of vitamin B6 + SAMe be
represented in this model.

5.3 Treatments Post-APAP
Effect of 250 mg/kg APAP 1 hour prior to 500 mg/kg SAMe dose
We have established a role of SAMe in protecting the liver from APAPinduced hepatic toxicity. However, to be effective as a therapeutic agent, SAMe
needs to be administered after APAP overdose.

To illustrate the potential

therapeutic benefits of SAMe, animals were given an overdose of APAP (250
mg/kg) and 1 hour later a treatment of 500 mg/kg SAMe was injected, i.p.
Severe hepatic stress was illustrated 4 hours post-APAP injection by
increased liver weights, high plasma ALT values, severe centrilobular necrosis
and decreased GSH levels. Animals given SAMe 1 hour post-APAP showed
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almost 100% recovery in all parameters measured. Liver weights were normal,
plasma ALT values were significantly decreased and there was no centrilobular
necrosis present. The most remarkable protection seen was the rise in GSH
levels. These levels had completely recovered and were statistically similar (p <
0.05) to the VEH and SAMe groups.
These data portrayed some remarkable results. They not only showed the
abilities of SAMe to attenuate APAP-induced hepatic stress, but they also
reinforced the hypothesis of one potential mechanism of SAMe (Lu, 1998). We
hypothesize injection of SAMe after the APAP-induced depletion of GSH allowed
more efficient use of this substrate for the production and thus restoration of GSH
levels. This need was so strong that the GSH-producing mechanism of SAMe
remained in a feed-forward manner until enough GSH was produced and
reversal and/or prevention of damage was carried out. We were now seeing
even stronger protection, probably based on the circumstance of a desperate
need for GSH production due to the APAP overdose. However, the possibilities
of other potential protective mechanisms still present itself with these results.
While GSH is a strong antioxidant, we did see positive results with SAMe in the
pre-treatment experiments when GSH levels were not as high.

Effect of 250 mg/kg APAP 1 hour prior to 204 mg/kg NAC dose
We had been able to directly compare the protective benefits of SAMe and
NAC throughout the experiments thus far, therefore to fully quantify the results
seen with the SAMe post-treatment, a study was conducted to display the
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abilities of NAC to attenuate APAP-induced toxicities. The treatment of NAC was
injected 1 hour post-APAP at a similar mmol concentration of SAMe.
As expected, similar results regarding hepatic induced stress given by 250
mg/kg APAP was recorded. NAC treatments were able to attenuate the APAPinduced hepatic toxicity, but in some cases not as well as SAMe. For instance,
liver weights were not reduced when the NAC post-treatment was given.
Furthermore, histological slides showed signs of centrilobular necrosis still
present. Both liver weight and histological values were similar to the VEH when
SAMe was given as treatment for APAP overdose in the mice.
Consequently, NAC was able to significantly decrease plasma ALT values
and increase hepatic GSH levels. Even though GSH levels were increased with
the NAC post-treatment, the values were not as high as those shown in the
SAMe post-treatment. These data force the question of which treatment should
be elicited post-APAP induced hepatic toxicity.

Data shown thus far have

suggested that, under our experimental conditions, SAMe post-treatment is more
effective than NAC in reversing APAP-induced hepatotoxicity. Further studies
involving these treatments, as well as higher concentrations of both treatments
should be conducted to fully illustrate the capabilities of SAMe vs. NAC.

5.4 Mitochondrial Isolation: Treatments Post-APAP
Effect of 250 mg/kg APAP 1 hour prior to 500 mg/kg SAMe dose
It is known that cytosolic GSH is the first line of defense against toxicants
such as NAPQI and that under severe stress, mitochondrial GSH can become
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depleted. However, the effect of SAMe on mitochondrial GSH is not well known.
To establish a better understanding of the protective abilities of SAMe as well as
try to create a proposed mechanism by which SAMe elicits its protective effects,
this experiment was designed to show the aptitude of APAP to deplete
mitochondrial GSH and the possible ability of SAMe to prevent (or restore) this
depletion.
Mitochondrial isolation was done similarly to Lash, 1999. After isolation,
LDH assays confirmed that mitochondria components were separate from other
cytosolic components.
APAP decreased GSH levels, but GSH levels in both the supernatant and
the mitochondria displayed no protection with SAMe when the treatment was
given post-APAP. One explanation for this lack of effect by SAMe on increasing
mitochondrial GSH levels could be the short post-treatment time frame. Since
GSH cannot be produced in the mitochondria, it has to be carried in via cellular
transport. This process requires time and energy. Whenever the cell is under
some sort of stress (such as APAP overdose), GSH production is a first priority.
Our previous data showed that SAMe was capable of restoring total cellular GSH
levels in APAP-treated animals. Another possibility could be the protein carriers
involved with GSH shipment into the mitochondria were altered. The protein
carriers are designed to recognize GSH and allow binding.

If the GSH is

conjugated or the protein carriers altered, GSH would possibly be unable to get
into the mitochondria.

We have illustrated with our proteomic studies some

proteins that become changed after a large dose of APAP. Further investigation
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regarding mitochondrial GSH concentrations will need to be investigated using
longer post-APAP time periods to determine the reason of why SAMe was not
increase mitochondrial GSH levels.
Nitrate and nitrite production are typically used as markers of nitric oxide
(NO) production. These analytes by themselves are unable to address the
possible adverse effects associated with its reaction with free radical species in
vivo. Active NO metabolites can react with superoxide to form peroxynitrite, a
powerful oxidant and nitrating agent. Subsequent reaction of peroxynitrite with
proteins results in nitrotyrosine formation. As a stable end product of peroxynitrite
mediated oxidation/nitration, nitrotyrosine can be used as a surrogate index of
NO dependent damage in vivo.
Nitrotyrosine levels in the mitochondria were analyzed using Western
blotting as another measure of the oxidative effects within the mitochondria
produced by APAP. Initial results suggest that SAMe reduces the amount of
nitrotyrosine-adducted proteins in APAP treated mice. SAMe had no effect on
nitrosylation of proteins when compared to VEH. Despite the inability of SAMe to
produce GSH within 3 hours of treatment (4 hours post-APAP), it was able to
decrease the levels of nitrotyrosine within the mitochondria. This too strengthens
our hypothesis that SAMe is working via other mechanisms other than GSH
production. This, to our knowledge, is the first study conducted investigating the
effects of SAMe protection within the liver mitochondria post-APAP overdose.
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Effect of 250 mg/kg APAP 1 hour prior to 204 mg/kg NAC dose
To illustrate and directly compare SAMe to NAC, a similar study was
conducted involving mitochondrial isolation and NAC (1.25 mmol/kg). To our
knowledge, a study including the involvement of NAC and the protection of
mitochondrial GSH has not been done. Furthermore, a direct comparison of
NAC vs. SAMe investigating protection/production of mitochondrial GSH has
never been reported.
Similar to SAMe, NAC did not reverse the APAP-induced depletion of
GSH in the mitochondria. Comparably to SAMe, additional time may be required
in order for NAC to replenish mitochondrial GSH. It is not known how long newly
produced GSH takes to get into the mitochondria after APAP-induced depletion.
Therefore, just as with SAMe, further investigation into the effects on
mitochondrial GSH with NAC and/or SAMe need to be done to better understand
this principle.
Nitrotyrosine levels in the mitochondria post NAC + APAP treatment were
also analyzed using Western blotting. In contrast to the effect of SAMe, NAC did
not reduce the amount of nitrotyrosine-adducted proteins when given 1 hour
post-APAP.

NAC had no effect in producing nitrosylated proteins when

compared to VEH. These data are supportive of the hypothesis that SAMe may
in fact attenuate severe hepatic damage following APAP overdose more
efficiently than NAC by another mechanism.
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5.5 Summary For Pre-Treatments
Effect of 500 mg/kg SAMe, 204 mg/kg NAC, 250 mg/kg SAMe + 102 mg/kg NAC
or 500 mg/kg SAMe + 3.84 mg/kg Vitamin B6 just prior to 300 mg/kg APAP
The overall summary for each treatment showed some protection in at
least one of the measurable parameters conducted. Some of the treatments
showed matching protective abilities, while some treatments showed a much
better ability to attenuate APAP-induced hepatic toxicity. Table 34 summarizes
the results of the pretreatment studies and figures 68 and 69 show a summary of
OxyBlot and 4HNE blots of the treatments. All animal preparations were identical
and can be reviewed in the previous results sections. Direct comparisons can be
drawn for each of the treatments and are the same on a mmol basis.
From the results in the table and the Western blots (FIGURES 68 AND
69), conclusions can be drawn on the benefits of each pretreatment in protecting
against APAP-induced hepatic toxicity. From these data, as well as the gels
shown in the results section, we can see that on a mmol basis SAMe protects
better than all other studied treatments. Despite being the drug treatment of
choice for APAP overdose cases, NAC did not yield as many protective effects
as did SAMe. NAC and SAMe do possibly work via different mechanisms, but
these mechanisms do not produce synergistic protection when given together.
Vitamin B6 may very well be a rate limiting factor in the production of GSH from
SAMe, but further studies must be conducted using a vitamin B6 + SAMe mixture
post-APAP treatment to address this hypothesis.
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Treatment

GSH

Liver Weight

NAC

30%

6%

SAMe

53%

8%

SAMe + NAC

30%

7%

SAMe + Vitamin B6 41%

8%

ALT
No protection
63%
No protection
46%

TABLE 34. Summary of pretreatment protection seen 4 hours post APAP.
These results summarize the protective effects seen of each of the major
parameters measured. As seen in the table, SAMe produced the most favorable
protective effects of all other treatments. These results were calculated based on
percent changes of APAP vs. Pretreatment + APAP within their experimental
data set. Values were rounded to the nearest whole number.

196

S+A

N+A

APAP

NAC

SAMe

VEH

115.5 kDa

82.2 kDa
64.2 kDa
48.8 kDa
37.1 kDa

FIGURE 68. OxyBlot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1 vehicle, Lane 2 SAMe, Lane 3 NAC, Lane 4
APAP, Lane 5 NAC 1 hour post-APAP (N + A) and Lane 6 SAMe 1 hour postAPAP (S + A). SAMe was administered as 500 mg/kg and NAC was given as
204 mg/kg, i.p. APAP was injected i.p. at a dose of 250 mg/kg (15 ml/kg). VEH
animals were injected i.p. with water (15 ml/kg).
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N+A

S+A

APAP

NAC

SAMe

VEH

115.5 kDa
82.2 kDa
64.2 kDa

48.8 kDa
37.1 kDa

FIGURE 69. 4HNE Blot of samples 4 hours post-APAP injection.
Lanes are denoted as: Lane 1 VEH, Lane 2 SAMe, Lane 3 NAC, Lane 4 APAP,
Lane 5 SAMe 1 hour post-APAP and Lane 6 NAC 1 hour post-APAP. SAMe was
administered as 500 mg/kg and NAC was given as 204 mg/kg, i.p. APAP was
injected i.p. at a dose of 250 mg/kg (15 ml/kg). VEH animals were injected i.p.
with water (15 ml/kg). Highlighted region represents area of greatest differences.
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5.6 Summary For Post-Treatments
Effect of 500 mg/kg SAMe or 204 mg/kg NAC 1 hour after 300 mg/kg APAP
SAMe and NAC protected against APAP-induced hepatic toxicity. Both
SAMe and NAC reduced plasma ALT levels, reduced oxidative stress and
significantly increased GSH levels. However, SAMe was able to protect to a
greater extent than NAC.

SAMe produced higher amounts of GSH and

decreased oxidized proteins more than NAC. These data imply that SAMe is
possibly more potent than NAC and provides better protection against APAPinduced oxidative stress. 4-Hydroxy-2-nonenal and protein carbonyls have been
extensively studied and are known to cause severe damage (Renes et al., 2000;
Schaur, 2003; Yang et al., 2003), with high protein carbonyl concentration
possibly leading to Alzheimer’s disease (Picklo et al., 2002).

SAMe, as

discussed previously in the results section, provides a larger area of protection
with regards to these parameters than does NAC.
The mechanism of GSH production by SAMe against APAP-induced
oxidative stress is supported by the data published by Lu (1998). However, this
research yielded some very interesting results forcing the question of possibilities
of other mechanisms regarding SAMe. It is very possible that the mechanism of
SAMe is further delineated to produce other protective effects as displayed in the
results of this study. This hypothesis is made stronger by the other protective
effects given by SAMe: lower liver weight, reversal of centrilobular necrosis,
decreased plasma ALT values, increased GSH levels, decreased nitrosylatedprotein levels within the mitochondria and decreased protein oxidation.
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It is

unlikely that all of these protective effects stem from GSH production by SAMe.
This hypothesis can be based on the results seen in the pre-treatment studies.
GSH production in animals dosed with SAMe just prior to APAP was not as
significant as the post-treatment studies, but there was still protection seen.
Further work is required to elucidate non-GSH dependent mechanisms by which
SAMe protects against APAP-induced liver damage.

5.7 HPLC Analysis
Investigation into the production and quantification of particular APAP
metabolites was studied to better diagram the mechanisms of both SAMe and
APAP. We had shown protective capabilities by SAMe for APAP toxicity, but it
became apparent that other possible mechanisms SAMe attenuation may exist.
To explore this possibility, we utilized HPLC protocols to identify effects of SAMe
on APAP metabolism. If SAMe was able to affect the production of particular
APAP metabolites, we could therefore draw a stronger conclusion to our belief of
other protective pathways of SAMe.
Techniques to isolate and quantitate the metabolites of these two drugs
have been developed (Aboul-Enein and Abu-Zaid, 2001; Dietze et al., 1997;
Esteban et al., 1992; Esteban et al., 1993; Wang 2001; Fischer et al., 1981;
Hamedani et al., 1993; Jensen et al., 2004; Miners et al., 1984; Vertzoni et al.,
2003; Wang and Cederbaum, 2006; Moldéus, 1978), but none had looked at the
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effects of SAMe on APAP metabolites.

We chose to use the methods as

published in Vertzoni et al. (2003) and Moldéus (1978).
Results from the HPLC showed differences in APAP and APAP-SO4
concentrations in both the liver and plasma at specific time frames. Whenever
SAMe was given as a pre-dose to APAP, we saw higher concentrations of APAP
and APAP-SO4 in the plasma (as compared to animals given only APAP). On
the other hand, we saw higher concentrations of APAP-SO4 in the liver when
SAMe was given just prior to APAP (when directly compared to animals dosed
with only APAP). These statistical differences (p < 0.05) allow us to further
question the abilities of SAMe on attenuating APAP-induced hepatic toxicity. For
instance, we know that SAMe produces GSH, but what we do not know are the
effects of SAMe on particular enzymes such as CYP2E1, the enzyme
responsible for the production of NAPQI.

There is also no published data

documenting the effects of SAMe on other protective mechanisms in the body
involved with attenuating APAP overdoses. These other protective mechanisms
include glucuronidation and sulfation of APAP.
Investigation of metabolites produced when APAP is injected and directly
comparing those results to animals dosed with both SAMe + APAP will help us to
further understand the metabolic processes of both SAMe and APAP. It will also
help strengthen our hypothesis that SAMe works via other mechanisms besides
GSH production. This data does in fact support our hypothesis that SAMe may
be involved in effecting the activity of CYP2E1, the enzyme responsible for the
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production of the toxic APAP metabolite NAPQI, and production of other
metabolites involved with APAP, such as APAP-Glucuronide and APAP-sulfate.
This HPLC data shows that SAMe is affecting APAP metabolism (higher
concentrations of APAP in the plasma) and the production of sulfate, as shown
by the APAP-sulfate conjugation concentration increases in the liver and plasma.
Further investigation regarding metabolites produced during APAP overdose, as
well as the metabolites produced during SAMe treatment + APAP, will help to
further define these possible mechanisms and answer the questions involved
protective effects seen with SAMe.

5.8 Proteomics
The limitation of this set of experiments was that analysis was performed
on individual bands from a gel. While this experiment allowed us to achieve
better coverage of proteins identified, it did not allow us to identify all of the
adducted proteins. Table 33 gives just a glimpse of some of the altered proteins
that we have identified during APAP overdose.
Future experiments will involve multidimensional protein identification
technology (MuDPIT).

For this procedure, the Dr. Lau at the University of

Arizona, will run a gel as previously described, but instead of digesting a select
number of bands, the entire lane will be digested and then loaded on the mass
spectrometer for MuDPIT analysis.

Then by using X!Tandem, PMOD, and

SpecPlot we will be able to globally identify and validate 4HNE adducts that are
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unique to the APAP treated group as well as those unaltered after SAMe + APAP
administration. Additionally, we will also begin searching for NAPQI and other
APAP metabolites adducts on liver proteins using a similar approach. These
future studies will help identify some of the pathways taken during APAP
overdose. It will also, of course, help describe some of the effects of SAMe
regarding the prevention of protein alterations during APAP-induced damage.

5.9 Future Studies
The current study was designed to address many aspects involving the
mechanistic properties of SAMe, including the ability of SAMe to attenuate forms
of APAP-induced hepatic toxicity.

This study also reproduced previously

published data showing that SAMe produces GSH (Lu, 1998). However, this
investigation has also raised other questions involving SAMe. For instance, our
data indicate that SAMe works, at least in part, via other non-GSH dependent
mechanisms.

These questions that have arisen include other antioxidative

properties of SAMe. For instance, how is SAMe preventing the production of
protein carbonyls and 4HNE adducted proteins when given just prior or 1 hour
post-APAP?

How does a dosing of SAMe effect the production of certain

metabolites produced when APAP is injected (i.p.)? Why are there protective
effects seen within 1 hour of SAMe treatment just prior to APAP injection, but
GSH production is not statistically significant?

Also, questions involving

protection seen using SAMe to decrease plasma ALT values and liver weights
when given just prior or post-APAP forces the question of other mechanistic
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properties of SAMe. It is because of the data collected during this study that
these questions have been asked. While our data does in part support that of Lu
(1998) and others (Stramentinoli, 1979), it also raises the possibility that GSH
production may not be the only mechanism by which SAMe protects the liver
against APAP-induced effects.

Further support for this conclusion is seen

involving studies using NAC. Even though NAC was able to protect the liver, to
some extent, against APAP-induced hepatic toxicities, and was able to restore
GSH levels, it was not as effective as SAMe when given at the same equimolar
dose. This not only suggests that SAMe is more potent than NAC, but SAMe
may also be working via different mechanisms to elicit more protective effects.
These questions, as well as future studies, are discussed below.
As stated in a paper published by Lu (1998), vitamin B6 is of vital
importance in the production of GSH from SAMe. We tried to demonstrate the
dependence of SAMe on vitamin B6 in our mouse model, but were unable to
show a significant difference with adding vitamin B6 vs. SAMe by itself. The
probable reason for these results is that GSH stores had not yet been completely
depleted and there was not an immediate need for new GSH to be produced.
We now know that GSH production is time-dependent when involving SAMe. A
better protocol for demonstrating the limiting effects of vitamin B6 on SAMedependent GSH production might be the recovery model as described
previously. In a recovery study animals are first dosed with APAP, then 1 hour
post-APAP they are injected with SAMe + vitamin B6. This experiment could
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prove the hypothesis of Lu (1998) as well as what we have previously stated: if
there is no direct and/or immediate need for GSH, no GSH is produced.
We saw a change in mitochondrial GSH 4 hours post-APAP injection. The
level of GSH within the mitochondria, as well as the cytosol, yielded significant
decreases after APAP was administered. Both SAMe and NAC were unable to
prevent the decrease of GSH within the mitochondria. However, 3 hours after
administering SAMe (4 hours post-APAP), there was a trend of higher levels of
GSH within the mitochondria. This data is enough to question the involvement of
SAMe in protecting the mitochondria from damage elicited by APAP overdose.
Further investigation involving longer time frames could produce even more
information regarding this protective effect. As mentioned earlier, GSH is not
produced within the mitochondria. Instead, any GSH found in the mitochondria
has been brought in from the cytosol. Measurements of GSH levels after longer
time frames post-APAP would illustrate another possible protective ability of
SAMe.

This type of study would give a pharmacokinetic view of SAMe

production of GSH and the time frame for the GSH to get into the mitochondria.
Proteomics is a rapidly growing field with new technologies advancing
very quickly. With the availability of this new technology comes opportunity to
better the understanding of how APAP elicits its damaging effects and how
SAMe is able to attenuate and/or reverse this damage. There have been several
articles published discussing different approaches and methods of isolating
proteins (Craven et al., 2002; Isozaki et al., 2002; O’Connell and Stults, 1997;
Shimazaki et al., 2004; Wang et al., 2003; Wu et al., 2005) as well as results
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from effects of certain toxins, such as cadmium (Chrestensen et al., 2000), on
protein modification. More importantly for our study, there have also been some
reports on APAP-induced alterations in proteins (Fountoulakis et al., 2000;
Ruepp et al., 2002; Su et al., 2005; Sumioka et al., 2004) as well as effects of
SAMe on proteins in the liver (Yang et al., 2004).

However, there is no

information regarding the effects of SAMe on altered proteins caused by APAP
overdose. This study will carry the protein carbonyl and 4HNE data further. We
already know that SAMe can decrease the concentrations of both protein
carbonyls and oxidized proteins; this study is meant to try and identify the
specific proteins SAMe protects.
This set of proteomic experiments will continue to be completed in
collaboration with Dr. Serrine Lau, Director, Southwest Environmental Health
Sciences Center, University of Arizona. Samples are first tested in our laboratory
for protein concentration, protein carbonyl alteration and 4HNE values. Dr. Lau
and associates then test the samples for specific protein changes. To date, we
have identified several proteins altered by APAP overdose.

We have also

identified these same proteins to remain unchanged/protected whenever SAMe
is given just prior to APAP. Further research into the role of proteins modified by
APAP will produce a better understanding of toxicity and how SAMe can protect
the liver against this APAP-induced damage. For example, SAMe may reduce
APAP mediated effects on mitochondrial proteins or enzymes that are involved in
repair or regeneration. In this situation, SAMe would act through a mechanism
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different from the current antidote, NAC and this would be a novel finding with
great potential for clinical relevance.
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Appendix
Buffer Preparation
Krebs-Ringer Buffer
(126.4 mM NaCl; 6.0 mM Na2HPO4; 5.2 mM KCl; 1.3 mM MgSO4; 1.0 mM CaCl2)
Into approximately 900 ml of deionized distilled water, the following salts were
added: 7.39 g NaCl; 852 mg Na2HPO4; 385 mg KCl; 318 mg MgSO4; 149 mg
CaCl2. The pH was adjusted to 7.4 with HCl. The volume was brought to 1 L with
deionized distilled water, followed by a final pH check. Prior to incubation the
buffer was oxygenated for 45 min.

Mitochondrial Isolation Buffer A
(225 mM sucrose; 3 mM KH2PO4; 5 mM MgCl2; 20 mM KCl; 20 mM
triethanolamine; 2 mM EGTA)
Into approximately 240 ml of deionized distilled water, the following salts were
added: 19.25 g sucrose; 102 mg KH2PO4; 254 mg MgCl2; 373 mg KCl; 746 mg
EGTA. The pH was adjusted to 7.4 with HCl. The volume was brought to 250 ml
with deionized distilled water, followed by a pH check.

Mitochondrial Isolation Buffer B
(225 mM sucrose; 3 mM KH2PO4; 5 mM MgCl2; 20 mM KCl; 20 mM
triethanolamine)
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Into approximately 240 ml of deionized distilled water, the following salts were
added: 19.25 g sucrose; 102 mg KH2PO4; 254 mg MgCl2; 373 mg KCl. The pH
was adjusted to 7.4 with HCl. The volume was brought to 250 ml with deionized
distilled water, followed by a pH check.

Glutathione Determination
Total glutathione (GSH) levels were measured based on the methods of
Anderson (1985). Following incubation, the tissues were rinsed in 3 ml of KrebsRinger buffer, blotted and weighed. Once weighed, the tissues were placed in
500 μl of 5% sulfosalycilic acid and homogenized followed by a rinse of the
homogenizer shaft with an additional 500 μl of 5% sulfosalycilic acid. The mixture
was centrifuged at 9000 g for 10 min at 4°C. The supernatant was decanted and
saved. For GSH levels, 25 μl of supernatant was combined with 175 μl water and
700 μl of 0.3 mM NADPH. Following a 10-minute incubation at 30 °C, 100 μl of 6
mM DTNB and 100 μl of glutathione reductase (16 units/ml) were added. The
samples were placed immediately into the spectrophotometer set at 412 nm and
the absorbance was read at 0, 15, 30, 60, and 90 seconds. Values were
calculated using a standard curve of reduced glutathione.

Glutathione disulfide (GSSG) levels were determined following 2-vinylpyridine
derivatization (Griffith, 1980). For GSSG levels, 25 μl of supernatant was
combined with 175 μl water. To this, 2 μl of triethylamine and 4 μl of 2vinylpyridine were added and the mixture was incubated for 30 min at room
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temperature. Following the incubation, 700 μl of 0.3 mM NADPH was added with
an additional 10-minute incubation at 30°C. After this incubation, 100 μl of 6 mM
DTNB and 100 μl of glutathione reductase (16 units/ml) were added. The
samples were placed immediately into the spectrophotometer set at 412 nm and
the absorbance was read at 0, 15, 30, 60, and 90 seconds. Values were
calculated using a standard curve of GSSG.

4-Hydroxynonenal-Adducted Protein
Tissues were weighed and homogenized in Krebs-Ringer Buffer on ice in a 2 ml
total volume. Samples were stored a –80 °C until analysis. Samples were thawed
on ice. Protein concentrations were determined for each sample (Bradford,
1976). For each sample 100 µg protein equivalents were added, while H2O was
added to provide equal volumes. An equal volume of sample buffer was added
and samples were boiled for 5 min. Samples and standards were loaded onto a
polyacrylamide gel (12.5 % acrylamide) and electrophoresed at 65 volts for 17 hr.
The gel was then transferred to a nitrocellulose membrane at 100 volts for 90
min. To verify efficiency of transfer, the membrane was placed in Ponceau S
stain for visualization. The membrane was then rinsed with H2O at room
temperature under constant shaking to remove stain. The membrane was then
blocked with milk at room temperature under constant shaking for 1 hr. Rabbit
polyclonal

antibody

to

(E)-4-Hydroxynonenal

(anti-HNE

PAb)

(Alexis

Biochemicals, ALX-210-767) in blocking buffer was added and incubated
overnight at 40 °C under constant shaking. The membrane was then rinsed three
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times in TBST. Secondary antibody, goat anti-rabbit linked with horseradish
peroxidase, in blocking buffer was added and incubated at room temperature
under constant shaking for 90 min. The membrane was then rinsed three times in
TBST and once in TBS. Enhanced chemiluminescence substrate was added and
the membrane was wrapped in Saran wrap. The membrane image was then
transferred to Kodak Photographic film for visualization of 4hydroxynonelaladducted proteins.

Mitochondrial Isolation
Isolate liver and rinse in 3 ml ice cold Buffer A. Blot and weigh livers, remove
excess non-liver tissue. Add minced liver to 1.5 ml Buffer A and pour in ice cold
Teflon homogenizer. Homogenize approximately 20 strokes. Adjust volume to 3
ml with Buffer A.

Centrifuge total mixture at 600 xg for 10 minutes at 4°C.

Remove and save supernatant.
minutes at 4°C.

Centrifuge supernatant at 15,000 xg for 5

Remove and dispose of fat layer on top of supernatant.

Remove supernatant and store aliquots for GSH, LDH and protein assays. Rinse
mitochondrial pellet with 250 µl of Buffer B. Re-suspend pellet in 1 ml of Buffer B
per gram tissue weight. Aliquot and store samples for GSH, LDH and protein
assays.
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